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Abstract
Diabetes is a growing, global concern, reaching a prevalence far beyond the projected 
statistics. Hyperglycemia is a common denominator of type 1 and type 2 diabetes mellitus that 
if left untreated, results in detrimental outcomes, e.g. oxidative damage. The pentose 
phosphate pathway (glucose-6-phosphate dehydrogenase [G6PD] and transketolase [TKT] 
as rate-limiting enzymes) offers an alternate ‟safer” route for excess metabolic fuels, while 
also replenishing anti-oxidant defenses and thus potentially offers value as a novel therapeutic 
target. As TKT-like 1 (TKTL1), a relatively novel member of the transketolase family, has been 
overlooked in this regard, we employed a TKTL1-knock-out (KO) mouse model as a targeted 
approach to evaluating TKTL1 function. Multiple low doses of streptozotocin (STZ) (40 mg/kg, 
intraperitoneal injections on five consecutive days) were used to induce hyperglycemia, a 
pathophysiologic state known to culminate in oxidative stress and damaging outcomes. 
Hyperglycemia incidence was 40% and 90% in wild-type (WT) and TKTL1-KO STZ-injected 
male groups, respectively, while only the TKTL1-KO STZ group displayed significantly higher 
blood glucose levels compared to the WT control (p<0.001) and the TKTL1-KO control group 
(p<0.001). The male TKTL1-KO STZ-treated group displayed larger relative liver weights 
(p<0.001) and kidney weights (p<0.05), respectively, compared to both WT and TKTL1-KO 
controls. Gastrocnemii weight of the TKTL1-KO STZ-treated group was lower than that of the 
WT control group (p<0.01). There was a significant, negative correlation between liver G6PD 
activity and blood glucose levels (Spearman’s correlation coefficient [r]=-0.37, p=0.03) while 
this correlation was not observed in cardiac tissue. In the latter, both TKTL1-KO groups 
displayed ~50% diminished transketolase activity compared to the WT control (p<0.001). No 
significant differences were noted in any of the oxidative stress and damage assessments of 
blood, heart, or liver samples. However, several adaptations were revealed in hepatic anti-
oxidant defenses: STZ-treated TKTL1-KO mice displayed increased catalase activity 
(p<0.05), with catalase activity showing a significant, positive correlation with blood glucose 
(r=0.39, p=0.02); ferric reducing anti-oxidant power (FRAP) concentrations as well as the 




reduced glutathione (GSH):to oxidized glutathione (GSSG) ratio were, significantly decreased 
in STZ-treated TKTL1-KO group (p<0.05) while both of these measurements were negatively 
correlation with blood glucose levels (r=0.45, p<0.01 for FRAP, r=-0.36, p=0.03 for 
GSH:GSSG ratio). Our data reveal that TKTL1 may play an anti-oxidant role in the liver to 
protect against hyperglycemia and to maintain overall glucose homeostasis. Thus our study 
demonstrates novel insights into TKTL1 function and shows that it remains a feasible 
therapeutic target for the treatment of diabetes. 
  





Diabetes is ‘n wêreldwye bekommernis waarvan die geprojekteerde voorkoms by verre 
onderskat is. ‘n Algemene kenmerk van tipe 1 sowel as tipe 2 diabetes mellitus is 
hiperglukemie wat lei tot skadelike uitkomste soos oksidatiewe skade. Die pentose-fosfaat 
padweg (PPP) (glukose-6-fosfaat dehidrogenase [G6PD] en transketolase [TKT] as tempo-
aangewende ensieme) bied ‘n alternatiewe, ‟veiliger” weg vir oorskot metaboliese brandstof 
terwyl dit ook antioksidante aanvul, dus is die PPP ‘n potensiële teiken vir behandeling. Siende 
dat ‘n ensiem soortgelyk aan TKT, TKTL1, se potensiaal in hierdie area van navorsing nog nie 
ontgin is nie het ons ‘n TKTL1-uitslaan (KO) muismodel gebruik as ‘n geteikende benadering 
om die funksie van TKTL1 te evalueer. Lae dosise van streptozotosien (STZ) (40 mg/kg 
daagliks op vyf agtereenvolgende dae) was gebruik om hiperglukemie, ‘n patologie 
geassosieer met oksidatiewe stress en skadelike uitkomstes, te bewerkstellig. Hiperglukemie 
voorkoms in die manlike STZ-behandelde groepe was 40% in wilde-tipe (WT) en 90% in die 
TKTL1-KO, waar slegs die TKTL1-KO groep wat STZ behandeling ontvang het, beduidend 
hoër bloedglukosevlakke getoon het in vergelyking met die WT kontrole groep (p<0.001). Die 
manlike TKTL1-KO STZ-behandelde groep se lewer- (p<0.001) en nier gewig (p<0.05) was 
verhoog in vergelyking met beide die WT en die TKTL1-KO kontroles. Inteenstelling hiermee, 
was die gastrocnemi spiere van die TKTL1-KO groep se gewig kleiner as dié van die WT 
kontrole groep (p<0.01). ‘n Beduidende, negatiewe korrelasie is opgemerk tussen lewer G6PD 
aktiwiteit en bloedglukosevlakke (Spearman se korrelasie koëffisiënt [r] =-0.37, p=0.03), wat 
nie in die hart van toepassing was nie. In hartweefsel het beide TKTL1-KO groepe ‘n ~50% 
verlaging getoon in TKT aktiwiteit in vergelyking met die WT kontrole (p<0.001). Geen 
beduidende veranderige in oksidatiewe stres en –skade asseseerings is gevind in bloed, 
hartweefsel of lewerweefsel nie. Hierinteen is verskeie aanpassings in die antioksidatiewe 
verdedigings meganismes opgelet. STZ-behandelde TKTL1-KO muise het verhoogde 
katalase aktiwiteit getoon (p,0.05) terwyl ‘n positiewe korrelasie ook opgemerk is tussen 
katalase aktiwiteit en bloedglukose vlakke (r=0.39, p=0.02); yster-reduserende antioksidant 




mag (FRAP) asook die fraksie van gereduseerde glutathione (GSH):geoksideerde glutathione 
(GSSG) was albei beduidend verlaagin die STZ-behandelde TKTL1-KO groep (p<0.05) terwyl 
beide van hierdie merkers ‘n negatiewe korrelasie met bloedglukosevlakke getoon het (r=0.45, 
p<0.01 vir FRAP, r=-0.36, p=0.03 vir GSH:GSSG fraksie). Ons data onthul ‘n antioksidatiewe 
rol vir hierdie ensiem in die lewer wat beskerm teen hiperglukemie en selfs kan byrae tot 
algehele glukose homeostase. Dus lewer ons studie nuwe insigte in die funksie van TKTL1 
wat steeds ‘n moontlike teiken is vir die behandeling van diabetes. 
Stellenbosch University  https://scholar.sun.ac.za
v 
Acknowledgements 
I would like to express my sincere gratitude to my supervisor and mentor, Professor M. Faadiel 
Essop, without which this project and my postgraduate career would not have been possible. 
I have learned so much from you the past two years both professionally and personally. You 
have the amazing ability to see the best in any situation no matter how awful it may seem. 
You inspire each person in CMRG to become the finest researcher and person they are 
capable of being. 
To Danzil Joseph, my co-supervisor, your guidance throughout my time in CMRG is absolutely 
invaluable. Your advice ‟control the controllables” which you so often gave, will stick with me 
forever. Thank you for your support throughout the past two years and especially for 
entertaining my random ideas about this project and helping me to sort through it all.  
Gaurang and Tanya, you made me feel at home in my visits to the Postdoc room and provided 
critical insights when I needed those most. Gaurang, thanks for the coffee breaks and chats 
about TKTL1 and my project.To the rest of CMRG, I would like to thank all of you for your 
support and advice throughout this degree, your input is greatly appreciated. 
Daleen you’re incredible! Your support and friendship during my time at the department kept 
me on track, while the mini-road trips to see ‟Sequel” and ‟Impi” kept me sane. Yigael, thanks 
for participating in the most random conversations and being my driving-buddy. The laughs 
with you have been priceless and much needed at times! Gustav, dankie dat jy geluister het 
as ek uit motivering uit gehardloop het en dat jy altyd in NARGA was al was dit net om te weet 
ek werk nie alleen nie. André, dankie dat jy kon sien presies wanneer koffiebreek benodig het 
en vir die ‟hoe gan dit met die skryf?” juis op die dae wat ek nie meer wou nie end it my 
gemotiveer het om aan te gaan. 
Aan my familie, baie dankie vir al die ondersteuning beide deur my studie loopbaan. Ek 
waardeer elke opoffering wat julle met graagte so deurgaan net sodat ek my studies kon 
voltooi. Dankie vir die laat aande wat Mamma spandeer het om my werk te proeflees. Aan die 
Joubert gesin, julle is ‘n absolute seën in my lewe. Julle bystand die afgelope paar jaar was 
onbeskryflik en ek waardeer dit ongelooflik baie.  




Table of Contents 
Abstract .............................................................................................................................. i 
Uittreksel ........................................................................................................................... iii 
Acknowledgements ........................................................................................................... v 
List of Tables ..................................................................................................................... xi 
List of Figures .................................................................................................................... xi 
List of Abbreviations ....................................................................................................... xvii 
Chapter 1: Introduction ...................................................................................................... 1 
1.1 Diabetes mellitus ............................................................................................................. 1 
1.1.1 Critical numbers of this international crisis ................................................................ 1 
1.1.2 Diabetes in South Africa ........................................................................................... 1 
1.1.3 Diabetes, closer to home – Western Cape ................................................................ 2 
1.2 Type 1 vs type 2 diabetes ............................................................................................... 2 
1.3 Hyperglycemia ................................................................................................................ 4 
1.3.1 The progression of hyperglycemia ............................................................................ 5 
1.3.1.1 Normal glucose homeostasis ............................................................................. 6 
1.3.1.2 Impaired glucose metabolism ............................................................................. 7 
1.3.1.3 Overt hyperglycemia .......................................................................................... 9 
1.3.2 Hyperglycemia and oxidative stress ........................................................................ 10 
1.3.2.1 Mitochondrial superoxide ................................................................................. 10 
1.3.2.2 Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) .......... 13 
1.3.2.3 Other sources and species of ROS .................................................................. 13 
1.3.3 Intracellular anti-oxidant mechanisms ..................................................................... 14 
1.3.4 Hyperglycemia and ROS enhances flux through metabolic circuits ......................... 15 




1.3.4.1 Advanced Glycation End-products ................................................................... 16 
1.3.4.2 Polyol pathway ................................................................................................. 16 
1.3.4.3 Protein kinase C ............................................................................................... 17 
1.3.4.4 Hexosamine biosynthetic pathway ................................................................... 17 
1.3.5 Effect of hyperglycemia and downstream oxidative stress on the heart, liver, and 
circulation ........................................................................................................................ 19 
1.3.5.1 Effect of hyperglycemia and downstream oxidative stress on the heart ............ 19 
1.3.5.2 Effects of hyperglycemia-induced oxidative stress on the liver ......................... 21 
1.3.5.3 Effects of hyperglycemia-induced oxidative stress in circulation ....................... 22 
1.4 Pentose Phosphate pathway ......................................................................................... 22 
1.4.1 Effect of hyperglycemia on the PPP .................................................................. 25 
1.4.2 Enhancing flux via the PPP and benefits ........................................................... 25 
1.5 The transketolases ........................................................................................................ 26 
1.5.1 Transketolase structure .......................................................................................... 26 
1.5.1.1 Interaction of transketolase with its cofactor – thiamine diphosphate ................ 28 
1.5.1.2 Transketolase activity ....................................................................................... 28 
1.5.1.3 Transketolase in diabetes ................................................................................ 29 
1.5.2 Transketolase-like 1 (TKTL1) .................................................................................. 32 
1.5.2.1 TKTL1 Structure and activity ............................................................................ 32 
1.5.2.2 TKTL1 in cancer ............................................................................................... 35 
1.5.2.3 TKTL1 in diabetes ............................................................................................ 40 
1.6 Problem statement and hypothesis ............................................................................... 41 
1.7 Aim and objectives ........................................................................................................ 41 




1.7.1 Aim ......................................................................................................................... 41 
1.7.2 Objectives ............................................................................................................... 41 
Chapter 2: Materials and Methods ................................................................................... 43 
2.1 Animals and ethics statement:....................................................................................... 43 
2.2 Genotyping analysis: ..................................................................................................... 43 
2.3 Experimental design: ..................................................................................................... 44 
2.4 Sample preparation: ...................................................................................................... 48 
2.4.1 Blood samples ........................................................................................................ 48 
2.4.2 Tissue samples ....................................................................................................... 48 
2.5 Assessment of the pentose phosphate pathway (PPP) ................................................. 48 
2.5.1 Glucose-6-phosphate dehydrogenase (G6PD) activity assay ................................. 48 
2.5.2 NADP+/ NADPH assay ........................................................................................... 49 
2.5.3 Transketolase activity assay ................................................................................... 50 
2.6 Determining the oxidative status of the serum and tissue .............................................. 51 
2.6.1 Indications of oxidative damage .............................................................................. 52 
2.6.1.1 NADPH oxidase (NOX) activity ........................................................................ 52 
2.6.1.2 Conjugated dienes (CDs) ................................................................................. 52 
2.6.1.3 Thiobutyric acid reactive substances (TBARS) ................................................. 53 
2.6.2 anti-oxidant mechanisms: ....................................................................................... 54 
2.6.2.1 Superoxide dismutase (SOD) activity assay ..................................................... 54 
2.6.2.2 Catalase ........................................................................................................... 54 
2.6.2.3 Ferric reducing anti-oxidant power (FRAP) ....................................................... 55 
2.6.2.4 Oxygen radical absorbance capacity (ORAC) .................................................. 55 




2.6.2.5 Glutathione levels ............................................................................................. 56 
2.7 Histological analysis ...................................................................................................... 57 
2.7.1 Sample preparation for histological analysis ........................................................... 57 
2.7.2 Hematoxylin and eosin (H&E) staining .................................................................... 58 
2.7.3 Sirius red stain: identifying possible fibrosis ............................................................ 58 
2.8 Western Blot analysis: apoptotic cell death ................................................................... 59 
2.9 Statistical Analysis ........................................................................................................ 60 
Chapter 3: Results ........................................................................................................... 61 
3.1 Genotyping of WT and TKTL1-KO mice to be used in this study ................................... 61 
3.2 Differential development of STZ-induced hyperglycemia ............................................... 62 
3.3 Body weights of male and female mice largely unaffected by STZ treatment ................ 65 
3.4 Assessment of organ weights in relation to body weight................................................ 65 
3.5 Analysis of the PPP ....................................................................................................... 67 
3.5.1 G6PD activity .......................................................................................................... 67 
3.5.2 NADPt concentration .............................................................................................. 70 
3.5.3 Transketolase activity ............................................................................................. 72 
3.6 Evaluation of oxidative status ........................................................................................ 75 
3.6.1 NOX activity ............................................................................................................ 75 
3.6.2 Quantification of CDs .............................................................................................. 78 
3.6.3 Quantification of TBARS in blood, heart, and liver samples .................................... 81 
3.6.4 SOD activity in heart and liver samples................................................................... 84 
3.6.5 Catalase activity in heart and liver samples ............................................................ 87 
3.6.6 FRAP measurements in blood, heart and liver samples .......................................... 89 




3.6.7 ORAC quantification in heart and liver samples ...................................................... 93 
3.6.8 The glutathione system ........................................................................................... 96 
3.7 H&E staining of heart and liver sections ...................................................................... 104 
3.8 Sirius red staining of heart and liver sections .............................................................. 106 
3.9 Semi-quantitative protein analysis with Western Blotting ............................................. 108 
Chapter 4: Discussion ................................................................................................... 110 
References .................................................................................................................... 120 








List of Tables 
Table 1.2.1 Comparison between T1DM and T2DM     3 
Table 1.3.1 Criteria for the diagnosis of pre-diabetes and diabetes   5 
Table 1.5.2.2.1 Summary of studies manipulating TKTL1 expression in cancer cell lines 
and main findings          36 
Table 1.5.2.2.2 Summary of studies investigating TKTL1 expression and influence in 
cancer            37 
Table 2.2.1 PCR cycling protocol        43 
Table 3.4 Organ weights as a percentage of body weight.    64 
 
List of Figures 
Figure 1.3.1.1.1 Humoral response of nondiabetic, impaired glucose tolerance (IGT) and 
non-insulin-dependent diabetes subjects (NIDDM or T2DM).    7 
Figure 1.3.2.1.1 The ETC under physiological and hyperglycemic conditions. 12 
Figure 1.3.3.1 Intracellular anti-oxidant systems that guard against oxidative stress.
            15 
Figure 1.3.4.1 Glycolytic metabolites enter NOGPs.     18 
Figure 1.4.1 Pentose phosphate pathway.       24 
Figure 1.5.1.1 Structure of human transketolase.      27 
Figure 1.5.1.2 Reactions catalyzed by human transketolase.    28 
Figure 1.5.1.3.1 BFT reverses hyperglycemia-induced NOGP activation.  30 
Figure 1.5.1.3.2 BFT activates PPP in an in vitro model of hyperglycemia.  31 
Figure 1.5.1.3.3 Expression patterns of transketolase and TKTL1 in leukocytes of 
control, pre-diabetic, and diabetic patients.      31 
Figure 1.5.2.1.1 Homology of TKTL1 based on the transketolase co-crystal structure 
with thiamine diphosphate-D-xylulose-5-phosphate adduct.    34 




Figure 1.5.2.2.1 A role for TKTL1 in cancer.      39 
Figure 2.3.1 A: (males). Illustration of the animal model and experimental design used to 
ascertain the role of TKTL1.        45 
Figure 2.3.1 B: (females). Illustration of the animal model and experimental design used 
to ascertain the role of TKTL1.        46 
Figure 3.1.1 Genotyping PCR analysis of WT and TKTL1-KO mice.   59 
Figure 3.2.1 Non-fasting blood glucose levels of female (A) and male mice: B (combined 
data), C (responding, WT-STZ), D (non-responding, WT-STZ) mice at termination (7 
weeks post-STZ protocol).         61 
Figure 3.2.2 Hyperglycemia incidence in male mice.     62 
Figure 3.2.3 Development of hyperglycemia – temporal analysis.   62 
Figure 3.3.1 Body weights of male (A) and female (B) mice were largely unchanged. 
            63 
Figure 3.5.1.1 G6PD activity in the heart: A (combined data), B (WT STZ responders), C 
(WT STZ non-responders).         66 
Figure 3.5.1.2 No significant correlation between G6PD activity in the heart and blood 
glucose concentrations.         66 
Figure 3.5.1.3 G6PD activity in the liver: A (combined data), B (WT STZ responders), C 
(WT STZ non-responders).         67 
Figure 3.5.1.4 Significant, moderate negative correlation of G6PD activity in the liver 
with increasing blood glucose concentrations.      67 
Figure 3.5.2.1 NADPt(NADPH+NADP+) in the heart: A (combined data), B (WT STZ responders), 
C (WT STZ non-responders).        68 
Figure 3.5.2.2 Lack of correlation between NADPt (NADPH+NADP+) levels and blood glucose 
concentrations in the heart.        69 
Figure 3.5.2.3 NADPt (NADPH+NADP+) in the liver: A (all data), B (responders), C (non-
responders).           69 
Figure 3.5.2.4 No correlation between NADPt (NADPH+NADP+) levels in the liver and blood 
glucose concentrations.         70 




Figure 3.5.3.1 Total transketolase activity in the heart: A (combined data), B (WT STZ 
responders), C (WT STZ non-responders).      71 
Figure 3.5.3.2 Lack of correlation between total transketolase activity in the heart and 
blood glucose concentrations.        71 
Figure 3.5.3.3 Total transketolase activity in the liver: A (combined data), B (WT STZ 
responders), C (WT STZ non-responders).      72 
Figure 3.5.3.4 Non-significant, moderately negative correlation between total 
transketolase activity in the liver and blood glucose concentrations.   72 
Figure 3.6.1.1 NOX activity in the heart: A (all data), B (responders), C (non-responders).
            74 
Figure 3.6.1.2 No correlation between NADPH oxidase activity in the heart and blood 
glucose concentrations.         74 
Figure 3.6.1.3 NOX activity in the liver: A (combined data), B (WT STZ responders), C 
(WT STZ non-responders).         75 
Figure 3.6.1.4 No correlation between NADPH oxidase activity in the liver and blood 
glucose concentrations.         75 
Figure 3.6.2.1 CDs in circulation: A (combined data), B (WT STZ responders), C (WT STZ 
non-responders).          76 
Figure 3.6.2.2 No correlation between CDs in the blood and blood glucose 
concentrations.          77 
Figure 3.6.2.3 CDs in the heart: A (combined data), B (WT STZ responders), C (WT STZ 
non-responders).          77 
Figure 3.6.2.4 No correlation between CDs in heart tissue and blood glucose 
concentrations.          78 
Figure 3.6.2.5 CDs in the liver: A (combined data), B (WT STZ responders), C (WT STZ 
non-responders).          78 
Figure 3.6.2.6 No correlation between CDs in liver tissue and blood glucose 
concentrations.          79 
Figure 3.6.3.1 TBARS in circulation: A (combined data), B (WT STZ responders), C (WT 
STZ non-responders).         79 




Figure 3.6.3.2 No correlation between TBARS in blood and blood glucose 
concentrations.          80 
Figure 3.6.3.3 TBARS in the heart: A (combined data), B (WT STZ responders), C (WT 
STZ non-responders).         80 
Figure 3.6.3.4 No correlation between TBARS in heart tissue and blood glucose 
concentrations.          81 
Figure 3.6.3.5 TBARS in the liver: A (combined data), B (WT STZ responders), C (WT STZ 
non-responders).          81 
Figure 3.6.3.6 No correlation between TBARS in liver tissue and blood glucose 
concentrations.          82 
Figure 3.6.4.1 SOD activity in the heart: A (combined data), B (WT STZ responders), C 
(WT STZ non-responders).         83 
Figure 3.6.4.2 No correlation between SOD activity in the heart tissue and blood glucose 
concentrations.          83 
Figure 3.6.4.3 SOD activity in the liver: A (combined data), B (WT STZ responders), C 
(WT STZ non-responders).         84 
Figure 3.6.4.4 No correlation of SOD activity in the liver tissue with blood glucose 
concentrations.          84 
Figure 3.6.5.1 Catalase activity of the heart: A (combined data), B (WT STZ responders), 
C (WT STZ non-responders).        85 
Figure 3.6.5.2 No correlation of catalase activity in the heart tissue with blood glucose 
concentrations.          86 
Figure 3.6.5.3 Catalase activity of the liver: A (combined data), B (WT STZ responders), 
C (WT STZ non-responders).        86 
Figure 3.6.5.4 Positive correlation between hepatic catalase activity and blood glucose 
concentrations.          87 
Figure 3.6.6.1 FRAP in circulation: A (combined data), B (WT STZ responders), C (WT 
STZ non-responders).         88 
Figure 3.6.6.2 Non-significant negative correlation between systemic FRAP levels and 
blood glucose concentrations.        88 




Figure 3.6.6.3 FRAP in the heart: A (combined data), B (WT STZ responders), C (WT STZ 
non-responders).          89 
Figure 3.6.6.4 No correlation between FRAP in the heart tissue and blood glucose 
concentrations.          89 
Figure 3.6.6.5 FRAP in the liver: A (combined data), B (WT STZ responders), C (WT STZ 
non-responders).          90 
Figure 3.6.6.6 Significant negative correlation between hepatic FRAP levels and blood 
glucose concentrations.         90 
Figure 3.6.7.1 ORAC in circulation: A (combined data), B (WT STZ responders), C (WT 
STZ non-responders).         91 
Figure 3.6.7.2 No correlation between systemic ORAC and blood glucose 
concentrations.          92 
Figure 3.6.7.3 ORAC in the heart: A (combined data), B (WT STZ responders), C (WT STZ 
non-responders).          92 
Figure 3.6.7.4 Non-significant positive correlation between cardiac ORAC and blood 
glucose concentrations.         93 
Figure 3.6.7.5 ORAC in the liver: A (combined data), B (WT STZ responders), C (WT STZ 
non-responders).          93 
Figure 3.6.7.6 No correlation between hepatic ORAC and blood glucose concentrations.
            94 
Figure 3.6.8.1 GSH in circulation: A (combined data), B (WT STZ responders), C (WT STZ 
non-responders).          95 
Figure 3.6.8.2 No correlation between GSH in the blood and blood glucose 
concentrations.          95 
Figure 3.6.8.3 GSSG in circulation: A (combined data), B (WT STZ responders), C (WT 
STZ non-responders).         96 
Figure 3.6.8.4 No correlation between GSSG in the blood and blood glucose 
concentrations.          96 
Figure 3.6.8.5 GSH:GSSG in circulation: A (combined data), B (WT STZ responders), C 
(WT STZ non-responders).         97 




Figure 3.6.8.6 No correlation between the blood GSH:GSSG and blood glucose 
concentrations.          97 
Figure 3.6.8.7 GSH in the heart: A (combined data), B (WT STZ responders), C (WT STZ 
non-responders).          98 
Figure 3.6.8.8 Non-significant positive correlation between GSH in heart tissue and 
blood glucose concentrations.        98 
Figure 3.6.8.9 GSH in the liver: A (combined data), B (WT STZ responders), C (WT STZ 
non-responders).          99 
Figure 3.6.8.10 No correlation between GSH in liver tissue and blood glucose 
concentrations.          99 
Figure 3.6.8.11 GSSG in the liver: A (combined data), B (WT STZ responders), C (WT STZ 
non-responders).          100 
Figure 3.6.8.12 Non-significant positive correlation between GSSG in liver tissue and 
blood glucose concentrations.        100 
Figure 3.6.8.13 GSH:GSSG in the liver: A (combined data), B (WT STZ responders), C 
(WT STZ non-responders).         101 
Figure 3.6.8.14 Significant negative correlation between GSH:GSSG in liver tissue and 
blood glucose concentrations.        101 
Figure 3.7.1 H&E stain of heart tissue 20X magnification (n=2).    102 
Figure 3.7.2 H&E stain of liver tissue 20X magnification (n=4).    103 
Figure 3.8.1 Sirius red stain of heart tissue 20X magnification (n=2).   104 
Figure 3.8.2 Sirius red stain of liver tissue.      105 
Figure 3.8.3 Sirius red stain of liver tissue 20X magnification (n=4).   106 
Figure 3.9.1 Western blot analysis of cleaved Caspase 3 (cCas-3) in the heart (A&C) and 
liver (B&D).           107 
Figure 4.1 TKTL1 offers protection against STZ.      112 
Figure 4.2 Proposed regulatory role for TKTL1 in glucose metabolism.  115 




List of Abbreviations 
A 
AAPH   2,2’Azobis(2-methylpropionamidine)-dihydrochloride 
Acetyl-CoA  Acetyl coenzyme A 
ADA   American diabetes association 
ADP   Adenosine diphosphate 
AGE   Advanced glycation end-products 
ANOVA  Analysis of variance 
ATP   Adenosine triphosphate 
B 
β-NAD   β-Nicotinamide adenine dinucleotide 
b.p.   Base pairs 
C 
Ca2+   Calcium 
CaCl2   Calcium chloride 
CDs   Conjugated dienes 
CoQ   Coenzyme Q 
C-terminal  Carboxy-terminal 
CytC   Cytochrome C 
D 
DETAPAC  diethylenetriamine-pentaacetic acid 
df   Dilution factor 
dH2O   Distilled water 
DTNB   5,5’-Dithiobis(2-nitrobenzoic acid) 
E 




e-   Electrons 
EDTA   Ethylenediaminetetraacetic acid 
Em   Emission 
eNOS   Endothelial nitric oxide synthase 
ETC   Electron transport chain 
Ex   Excitation 
F 
F6P   Fructose 6-phosphate 
FADH2   Flavin adenine dinucleotide 
FeCl3   Iron(III)chloride 
FGP   Fating plasma glucose 
FRAP   Ferric reducing anti-oxidant power 
G 
G3P   Glyceraldehyde 3-phosphate 
G6P   Glucose 6-phosphate 
G6PD   Glucose 6-phosphate dehydrogenase 
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase 
6-HD   6-hydroxydopamine 
GLUT   Glucose transporter 
GSH   Reduced glutathione 
GSSG   Oxidized glutathione 
H 
H&E   Hematoxylin and Eosin 
H+   Protons 
H2O   Water 
HbA1c   Glycated hemoglobin 




HBP   Hexosamine biosynthetic pathway 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid 
HIF-1α   Hypoxia-inducible factor 1 α 
HRP    Horseradish peroxidase 
I 
IFG   Impaired fasting glucose 
IgG   Immunoglobulin G 
IGT   Impaired glucose tolerance 
J 
K 
KCl   Potassium chloride 
KO   Knock-out 
L 
M 
M2VP   1-methyl-2-vinyl-pyridinium trifluoromethane sulphate 
MgCl2   Magnesium chloride 
MgSO4·H2O  Magnesium sulphate heptahydrate 
Mn-SOD  Manganese-dependent superoxide dismutase 
MPA   Metaphosphoric acid 
MPA   Malondialdehyde 
mPTP   Mitochondrial permeability transition pore 
N 
NaCL   Sodium chloride 
NADH   Nicotinamide adenine dinucleotide 
NADP+   Oxidized nicotinamideadenine dinucleotide phosphate 
NADPH  Nicotinamide adenine dinucleotide phosphate 




NADPt   Total NADP 
NC   Negative control 
NF-κB   Nuclear factor kappa-light-chain-enhancer of activated B cells 
NIDDM  Non-insulin-dependent diabetes mellitus 
NO   Nitric oxide 
NOGPs  Non-oxidative glucose pathways 
NOX   Nicotinamide adenine dinucleotide phosphate oxidase 
N-terminal  Amine terminal 
O 
O·2̄   Superoxide radical 
O2   Oxygen 
OGTT   Oral glucose tolerance test 
OH· ̄   Hydroxyl radical 
ONOO-  Peroxynitrite 
ORAC    Oxygen radical absorbance capacity 
P 
PARP   Poly-adenosine diphosphate-ribose polymerase 
Pi   Inorganic phosphate 
PI3K/Akt  Phosphatidylinositol 3-kinase/ Protein kinase B 
PKC   Protein kinase C 
PP   Pyrophosphate 
PPP   Pentose phosphate pathway 
Pyr   Pyrimidine 
Q 
R 
R5P   Ribose 5-phosphate 




RAGE   Receptor for advanced glycation end-products 
RLU   Relative light units 
Ru5P   Ribulose 5-phosphate 
S 
SANS   South African National Standards 
SEM   Standard error of the mean 
SOD   Superoxide dismutase 
SOD   Superoxide dismutase 
SSA   Statistics South Africa 
STZ   Streptozotocin 
T 
T-cells   Thymus cells 
T1DM   Type 1 diabetes mellitus 
T2DM   Type 2 diabetes mellitus 
TBA   Thiobutyric acid 
TBARS  Thiobutyric acid reactive substances 
TBARS  Thiobutyric acid reactive substances 
TCA   Tricarboxylic acid 
TDP   Thiamine diphosphate 
TKT   Transketolase 
TKTL1   Transketolase-like 1 
TKTL1-KO  Transketolase-like 1 knock-out 
TKTL2   Transketolase-like 2 
TPP   Thiamine pyrophosphate 
TPTZ   2,4,6-Tris(2-pyridyl)-5-triazine 
Tris   Trisaminomethane 




Tris-HCl  Trisaminomethane hydrochloric acid 
U 
UDP-GlcNAc  Uridine-N-acetyl glucosamine 
UV   Ultraviolet 
V 
vs.   Versus 
W 
WHO   World health organization 
WT   Wild type 
X 
X5P   Xylulose 5-phosphate 
Y 
Z 
Units and other 
%   Percent 
~   Approximately 
<   Smaller than 
>   Larger than 
∆   Change increment 
≥   Larger than or equal to 
°C   Degrees Celsius 
A   Absorbance 
AUC   Area under curve 
cm   Centimeter 
dl   Deciliter 




g   Gram 
g   Relative centrifuge force 
h   Hour 
kg   Kilogram 
L   Liter 
M   Molar 
mg   Milligram 
min   Minute 
mm   Millimeter 
mmol   Millimole 
mU   milliunit 
nm   Nanometer 
s   Second 
TE   Trolox equivalent 
U   Unit 
V   Volt 
v/v   volume per volume 
β   Beta 
ε   Extinction coefficient 
κ   Kappa 
 




Chapter 1: Introduction 
1.1 Diabetes mellitus 
Diabetes mellitus describes a group of metabolic conditions of manifold etiologies of genetic 
and environmental origin (World Health Organization [WHO], 2006). The most noticeable 
characteristics of diabetes include hyperglycemia and dysfunctional insulin secretion and/or 
action. The latter results in disturbed carbohydrate, protein and lipid metabolism. 
1.1.1 Critical numbers of this international crisis 
Diabetes is a growing concern worldwide as it is currently one of the major causes of mortality 
and disability (Murray et alet al., 2013). The mortality rate attributed to diabetes mellitus in 
2015 was 1.59 million – making it the sixth leading cause of death globally (WHO, 2017). 
Furthermore, a large percentage of diabetic individuals commonly remain undiagnosed (Bailey 
et alet al., 2016). Therefore, it is likely that the reported deaths attributed to diabetes are rather 
conservative and do not mirror the true danger of this disease. 
At the turn of the century, an estimated 171 million individuals worldwide suffered from 
diabetes (Wild et al., 2004). This number was expected to rise to 366 million by 2030; however, 
by 2008 it had already risen to 347 million (Shisana et al., 2013). In 2016, an estimated 422 
million of overall, global morbidity was attributed to diabetes (WHO, 2016). These statistics 
illustrate the epidemic proportions to which this disease has escalated in the past two decades. 
1.1.2 Diabetes in South Africa  
When focusing on South Africa, there is a paucity of epidemiological studies that rely on 
biomarkers to determine the prevalence of diabetes (Shisana et al., 2013). However, current 
data show that diabetes contributes ~6% to the morbidity in South Africa (WHO, 2016). 
A report compiled from the General Household Survey in 2011 indicated that 4.7% of the 
population were diagnosed with some form of diabetes (Statistics South Africa [SSA], 2013), 
while the The South African National Health and Nutrition Examination Survey [SANHANES-




1] reported a 10% prevalence of diabetes (glycated hemoglobin [HbA1c] > 6.5%, blood 
glucose > 7 mM) in the same population (Shisana et al., 2013). One major drawback of the 
data acquired from the General Household Survey report is that it relied solely on 
questionnaires and did not consider undiagnosed cases as there were no diagnostic tests 
involved. In the SANHANES-1 report the data consisted of a self-reported, previously 
diagnosed section as well as diagnostic testing of collected blood samples.  
1.1.3 Diabetes, closer to home – Western Cape  
In 2011, 6.8% of the Western Cape population was reportedly diagnosed with diabetes with 
the majority (98.4%) receiving treatment (SSA, 2013). Furthermore, a prevalence and 
management study in the region reported that among 12,496 individuals partaking in the study, 
9.4% suffered from diabetes (non-fasting blood glucose ≥ 11.1 mmol/L) (Bailey et al., 2016). 
Of these patients, 12.7% were previously undiagnosed and 59.4% of the self-reported 
diagnosed patients were not receiving treatment for this disease. These data suggest that the 
impact of diabetes is significantly undervalued. A report released by SSA confirmed diabetes 
as the leading underlying cause of mortality in 2015, with 7.2% of deaths in the Western Cape 
ascribed to this disease (SSA, 2017). Taken together these statistics indicate a somber future. 
1.2 Type 1 vs type 2 diabetes 
Diabetes is broadly classified into two subsets – type 1 and type 2 (WHO, 2006). Type 1 
diabetes mellitus (T1DM) accounts for ~10% of diabetic cases and is generally considered an 
autoimmune disorder (Gillespie, 2006; Jouvion et al., 2006). T1DM is broadly characterized 
by insulin deficiency and the need for insulin therapy from a relatively early stage. By contrast, 
type 2 diabetes mellitus (T2DM) is a metabolic disorder with insulin resistance the key feature 
(WHO, 1999). A common characteristic of both diabetes types is hyperglycemia, with varied 
pathophysiological consequences (discussed in more detail below, refer Table 1.2.1 for 
comparative assessment of T1DM and T2DM). 
 










FPG: ≥ 7.0 mM or HbA1c: ≥ 6.5% or 2-h plasma glucose*: ≥ 11.1 
mM  
Autoantibodies, autoantigens, decreased C-peptide. 
FPG: ≥ 7.0 mM or HbA1c: ≥ 6.5% or 2-h plasma glucose*: ≥ 11.1 
mM  
Bio-markers Classic: Hyperglycemia, ketonemia/ ketonuria, ↓ insulin and C-
peptide levels, reduced β-cell mass. 
Autoantibodies: glutamic acid decarboxylase, insulin and/ or islet 
cells. 
Antigens: human leukocyte antigen-related 
Classic: Hyperglycemia, hyperinsulinemia, hyperlipidemia. 
↑ Inflammatory markers 
↓ Anti-inflammatory markers 
Physical 
symptoms 
Classic: Polydipsia, polyuria, polyphagia, blurry vision, fatigue, and 
weight loss. 
Commonly asymptomatic. 
Complications Retinopathy, neuropathy, cardiovascular disease, hypoglycemia. Retinopathy, micro- and macrovascular complications, lower-limb 
ulcers, myocardial infarction. 
Etiology and 
risk factors 
Genetic: predisposition to the auto-immune destruction of 
pancreatic β-cells. 
Environmental: infection, insulin resistance, obesity, toxins 
(streptozotocin [STZ], alloxan, vacor), vitamin D deficit. 
Idiopathic: no known etiology.  




Dependent on insulin for survival. Weight reduction, increased physical activity, pharmacological 
treatments (metformin, intermediate-acting insulin, gliclazide). 
* Venous plasma glucose 2 hours after ingestion of 75 g oral glucose load. FPG: Fasting plasma glucose, HbA1c: glycated hemoglobin, STZ: 
streptozotocin. Diagnostic criteria compiled from WHO and American Diabetes Association (ADA) criteria.  
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The etiology of both T1DM and T2DM is multifaceted and is thought to include genetic 
predisposition as well as environmental stimuli (reviewed in Scheen, 2004). For T2DM the 
pathophysiology is predominantly associated with obesity, insulin resistance and 
hyperglycemia. These are interrelated and converge on the chronic availability of energy 
substrates, i.e. hyperglycemia and increased circulating free fatty acids and triglycerides 
(reviewed in Nolan et al., 2011). As the spotlight of this study is on hyperglycemia this will be 
the focus from now onwards.  
1.3 Hyperglycemia 
Hyperglycemia leads to robust uptake of glucose into insulin-independent tissues (Jagdale et 
al., 2016). It also triggers biochemical and electrophysiological perturbations that contribute to 
contractile dysfunction (Mapanga et al., 2014). For example, exposure to chronic 
hyperglycemia is often associated with increased incidence of acute myocardial infarction, 
macrovascular damage (e.g. stroke), diabetic cardiomyopathy and eventually heart failure, 
which together form the major causes of death in patients with diabetes (reviewed in Mapanga 
and Essop, 2016).  
Diabetes-related hyperglycemia also contributes to microvascular damage such as 
retinopathy and nephropathy which are relatively common occurrences in diabetic patients 
(Stratton et al., 2000; reviewed in Singleton et al., 2003). Here lower limb amputations strongly 
correlate with vascular complications and diabetes (Hämäläinen et al., 1999; Kurowski et al., 
2015). The kidneys and the liver which play vital roles in metabolism and detoxification - are 
also vulnerable to the effects of hyperglycemia (refer Section 1.3.5). Furthermore, pancreatic 
β-cells are particularly susceptible to hyperglycemic damage which can induce islet formation 
to compensate for increased apoptosis in these regions (Bonner-Weir et al., 1989). The 
eventual failure of this adaptation is thought to underlie progression to overt hyperglycemia 
and diabetes (discussed below). By contrast, the liver is predisposed to mitochondrial 
dysfunction prompted by hyperglycemia. This has been shown in a variety of cell culture and 




animal models that utilized a range of diabetes-inducing agents such as alloxan and 
streptozotocin (STZ), as well as in human studies (reviewed in Dey and Swaminathan, 2010).  
The literature reviewed indicate the intricate nature of hyperglycemia as it affects numerous 
organs in a distinct fashion. Before we consider the mechanisms at play in hyperglycemia-
induced damage, it is important to first examine the onset of hyperglycemia. 
1.3.1 The progression of hyperglycemia 
The concentration of glucose in the blood is determined by two critical factors, the rate of 
glucose entering the bloodstream and its rate of clearance from circulation (Dinneen, 1997). 
When homeostasis of either of such processes is disturbed then hyperglycemia ensues. 
Hyperglycemia in the context of diabetes management is commonly divided into a number of 
pathological stages (Table 1.3.1) – normoglycemia (non-diabetic), impaired fasting glucose 
(IFG) and impaired glucose tolerance (IGT, pre-diabetes), and hyperglycemia (diabetes) 
(Seino et al., 2010). Before considering the derangement of glucose homeostasis, the 
maintenance of glucose homeostasis in normoglycemic individuals will be discussed. 
Table 1.3.1 Criteria for the diagnosis of pre-diabetes and diabetes 
 











<6.1 mmol/L Between 6.1 
and 6.9 
mmol/L 
<7.0 mmol/L ≥7.0 mmol/L 
Non-fasting blood 
glucose 
~5.1 mmol/L   ≥11.1 mmol/L 
Oral glucose 
tolerance test 
<7.8 mmol/L <7.8 mmol/L ≥7.8 and <11.1 
mmol/L 
≥11.1 mmol/L 
HbA1c    ≥6.5% 




1.3.1.1 Normal glucose homeostasis 
Under fasting conditions, blood glucose concentrations are maintained at roughly 5 mmol/L 
and this occurs by glucose transporter (GLUT)-2 that is expressed in the liver (Unger, 1991). 
The liver produces glucose via glycogenolysis and gluconeogenesis where glucose is 
secreted into the bloodstream to prevent hypoglycemia (reviewed in Dinneen, 1997). This 
intricate balance is sustained by two antagonistic hormones: insulin and glucagon (Unger and 
Orci, 1981). In the fasting state, glucagon (secreted by pancreatic ɑ-cells) primes the liver to 
secrete glucose which is subsequently used by the brain and other tissues as a fuel substrate 
(reviewed in Unger, 1991). 
Upon the ingestion of a carbohydrate-containing meal, glucose from the gastrointestinal tract 
enters the bloodstream. This action triggers GLUT-2 receptors on pancreatic -cells which 
respond with insulin secretion in two phases (Ceriello and Motz, 2004; reviewed in Unger, 
1991). The first phase is a pronounced, acute entry of insulin into the bloodstream triggering 
GLUT-4 translocation to the plasma membrane on insulin-sensitive tissues (muscle and 
adipose tissue) via the phosphatidylinositol 3-kinase (PI3K)/Protein kinase B (Akt) pathway 
(Bergman et al., 1981, reviewed in Leahy, 2005; Sano et al., 2003). Here, glucose enters the 
tissue at a rate matching its entry into circulation thereby allowing the return to normoglycemia 
(Maruyama et al., 1984). Concurrently, insulin impedes glucagon secretion from pancreatic ɑ-
cells thereby suppressing hepatic glucose release and promoting its uptake. In this phase, 
glycogenesis and protein synthesis are stimulated, lipolysis attenuated, and energy levels 
maintained by glucose breakdown (reviewed in Baumgard et al., 2016; reviewed in Dinneen, 
1997). The second phase of insulin secretion is a slow-release response which persists until 
normoglycemia is restored (reviewed in Leahy, 2005).  
The dysregulation of glucose homeostasis is commonly verified with the testing of glucose 
tolerance. This is accomplished by monitoring glucose levels for two hours after the delivery 
of an oral or intravenous glucose bolus (Figure 1.3.1.1.1) (reviewed in Leahy, 2005; Scheen, 




2004; Seino et al., 2010). This is commonly referred to as an oral glucose tolerance test 
(OGTT). 
 
Figure 1.3.1.1.1 Humoral response of nondiabetic, impaired glucose tolerance (IGT) and 
non-insulin-dependent diabetes subjects (NIDDM or T2DM). In individuals with 
progressive hyperglycemic impairment, glucose concentration, as well as hormones such as 
insulin and glucagon, provide crucial information on the extent of the impairment. With the 
advancement of the dysfunction, glucose concentrations increase dramatically and remain 
relatively high. In parallel, the insulin response is delayed (IGT) or diminished (NIDDM), 
whereas glucagon levels remain relatively high (Butler and Rizza., 1991; reviewed in Dinneen, 
1997). 
1.3.1.2 Impaired glucose metabolism 
In individuals with IGT, the first-phase insulin response is deferred (Figure 1.3.1.1.1). This is 
accompanied by periods of intermittent postprandial hyperglycemia as the rate of glucose 
clearance is attenuated (Butler and Rizza., 1991). Various mechanisms are proposed to 
explain the delayed responsiveness to postprandial hyperglycemia, including impaired insulin 
secretion (Seltzer et al., 1967; reviewed In Dinneen, 1997). 




Decreased insulin and GLUT-2 mRNA levels are routinely found with IGT (Polonsky et al., 
1996). This translates to attenuated pancreatic β-cell function as insulin output per cell is 
diminished. To compensate for β-cell dysfunction, islet hyperplasia arises allowing for 
increased total insulin secretion – hyperinsulinemia (Polonsky et al., 1996). Although insulin 
secretion is defective in IGT, disrupted insulin action is thought to be the major contributor to 
postprandial hyperglycemia (Basu et al., 1997; reviewed in Dinneen et al., 1997). This 
suggests that insulin resistance precedes IGT and may therefore be one of the initial 
pathophysiological mechanisms by which it occurs. 
Insulin resistance of insulin-dependent tissues, especially muscle with GLUT-1 and GLUT-4 
transporters, has been investigated as a possible cause of IGT (Ebeling et al., 1998; Henriksen 
and Dokken, 2006). The hypothesis is that glucose taken up by GLUT-1 and GLUT-4 has 
different fates. Here glucose transported via GLUT-1 (insulin-independent) is phosphorylated 
by hexokinase I and is available for further metabolism by various pathways, while glucose 
taken up via the predominant glucose transporter – GLUT-4 (insulin-dependent) – is 
phosphorylated by hexokinase II and primarily metabolized by glycogenolysis and glycolysis 
(Ebeling et al., 1998). When systemic glucose levels rise, glucose uptake via GLUT-1 is 
augmented and excess intracellular glucose can enter the hexosamine biosynthetic pathway 
(HBP). This attenuates insulin-dependent GLUT-4 translocation to the plasma membrane and 
therefore less glucose is taken up by this transporter, i.e. insulin resistance (reviewed in 
Petersen and Shulman, 2006).  
Hyperinsulinemia has also been implicated in insulin resistance, especially in pancreatic β-
cells where the infusion of insulin led to alterations in GLUT-2 expression patterns and 
impaired signaling and function (Chen et al., 1990). Furthermore, it rendered pancreatic β-
cells increasingly unresponsive to the excess glucose in the bloodstream (Johnson et al., 
1990). A 25-year follow-up study of normoglycemic individuals with a predisposition to 
developing T2DM was crucial in delineating the mechanisms behind the transition from IGT to 
diabetes (Martin et al., 1992). Here individuals who underwent the transition to diabetes 




showed signs of a compensatory insulin response which declined gradually before the onset 
of diabetes (Martin et al., 1992). This was attributed to pancreatic β-cell decompensation, 
accompanied by increased superfluous hepatic glucose production and resulting in IFG 
(Efendić et al., 1985; Lillioja et al., 1993). A significant theme from the follow-up study was that 
insulin sensitivity and insulin-dependent glucose clearance inversely correlated with the risk 
of T2DM development. This was substantiated by insulin resistance strongly correlating with 
the progression of IGT and IFG to overt hyperglycemia (diabetes) (Knowler et al., 1990). 
1.3.1.3 Overt hyperglycemia 
The fasting state of T2DM is characterized by decreased glucose uptake in insulin-dependent 
tissues as well as increased hepatic glucose production which maintains chronic fasting 
hyperglycemia (reviewed in Unger, 1991). In the postprandial state, there is an influx of 
glucose from dietary substrates, causing extensive hyperglycemia (Figure 1.3.1.1.1). Unlike 
the normal response, pancreatic β-cells of diabetic persons are insensitive to increased blood 
glucose levels (delayed first phase response). This results in insufficient insulin secretion 
which in turn leads to decreased GLUT-4 translocation and attenuated glucose uptake 
(blunted first phase response) (reviewed in Polonsky et al., 1996). This signifies the 
decompensation of pancreatic β-cells as they can no longer maintain insulin levels high 
enough to overcome hyperglycemia (reviewed in Polonsky et al., 1996). Additional 
mechanisms of pancreatic β-cell dysfunction include reduced insulin gene expression due to 
deoxyribonucleic acid (DNA) damage and apoptosis of such cells (Pick et al., 1998; Piro et al., 
2002; Shimabukuro et al., 1998). Both mechanisms occur as a result of ‟glucolipotoxicity”, i.e. 
excessive amounts of intracellular glucose and fatty acids which trigger oxidative stress (Zhou 
and Grill, 1994; Sako and Grill, 1990; Piro et al., 2002). Moreover, glucagon inhibition by 
insulin is diminished and hepatic glucose production continues in the postprandial state 
(Efendίc et al., 1985; Lillioja et al., 1993). These compounding effects contribute to chronic 
hyperglycemia, with circulating glucose levels not returning to the normal, homeostatic range. 




The effect of chronic hyperglycemia on various mechanisms of oxidative stress and anti-
oxidant will now be discussed in more detail. 
1.3.2 Hyperglycemia and oxidative stress  
Various hypotheses have been proposed to explain the link between hyperglycemia and the 
development of diabetic complications. Some of these include the activation of protein kinase 
C (PKC), activation of the polyol pathway, increased formation of advanced glycation end-
products (AGEs), pseudohypoxia and oxidative stress (reviewed in Thornalley et al., 2001). In 
line with the focus of this project, we will focus on oxidative stress as a key mechanism 
responsible for hyperglycemia-induced damage. 
1.3.2.1 Mitochondrial superoxide 
Mitochondria are the powerhouses of the cell and play an essential role in maintaining 
intracellular energy homeostasis (Figure 1.3.2.1.1). However, under hyperglycemic conditions 
excess intracellular glucose availability causes mitochondrial energy production to become 
dysfunctional. This can be compared to a machine that becomes overheated and cannot 
function properly leading to damaging outcomes. Du and colleagues (2000) first proposed that 
hyperglycemia-related damaging effects are primarily mediated by excess mitochondrial 
reactive oxygen species (ROS), and specifically superoxide (O·2̄) production. 
Under normal conditions glucose enters glycolysis where it is metabolized to pyruvate in the 
cytosolic compartment. Pyruvate subsequently enters the tricarboxylic acid (TCA) cycle in the 
mitochondrion to generate e- donors, i.e. nicotinamide adenine dinucleotide (NADH) and flavin 
adenine dinucleotide (FADH₂). Such donors transfer electrons (e-) to complex I and II, 
respectively, while (in parallel) protons (H⁺) are transported to the impermeable mitochondrial 
intermembrane space (Figure 1.3.2.1.1). The e- are next shuttled by coenzyme Q (CoQ) to 
complex III, where cytochrome C (CytC) shuttles it to complex IV. Here the e- are transferred 
to oxygen (O₂) to form water (H₂O). Adenosine triphosphate (ATP) synthase subsequently 
utilizes the H⁺-gradient to convert adenosine diphosphate (ADP) and an inorganic phosphate 
(Pi) to ATP (reviewed in Brownlee et al., 2005). 




With excessive glucose availability a surplus of NADH and FADH2 are supplied to the electron 
transport chain (ETC) (Figure 1.3.2.1.1). Here it causes a progressive increase in 
mitochondrial membrane potential (above the physiological threshold) as H+ is continually 
pumped into the intermembrane space. When this occurs the e- transfer to complex III is 
hindered and trapped on CoQ. The latter subsequently donates a single e- to O₂, forming O·2̄, 
a volatile form of ROS. 
Increased O·2̄ levels can trigger DNA strand breaks which subsequently stimulates poly-ADP-
ribose polymerase (PARP) as a reparative mechanism (Du et al., 2003). As a secondary effect 
to PARP activation, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity is 
repressed by poly(ADP-ribosyl)ation (Du et al., 2003). This enzyme is crucial in glycolysis and 
its inactivity leads to a build-up of glycolysis intermediates that can be channeled into other 
metabolic pathways – non-oxidative glucose pathways (NOGPs – discussed in Section 1.3.2.2 
below) – with detrimental consequences (Brownlee et al., 2005). This sequence of events has 
been termed the ‟unifying hypothesis of hyperglycemic damage” and forms the premise of 
NOGP activation. Moreover, as hypothesized by Ebeling and colleagues (1998), glucose 
taken up by GLUT-1 can also be channeled through the NOGPs further exacerbating this cycle 
of activation. Although mitochondrial O·2̄ forms the basis of this hypothesis (backed by robust 
experimental evidence), additional sources and mechanisms of intracellular ROS production 
cannot be ruled out. For example, subsequent studies have lent credence to a more complex 
and interrelated set of mechanisms that may facilitate this (Joseph et al., 2014; reviewed in 
Schaffer et al., 2012; Serpillon et al., 2009). In line with this, we next discuss additional sources 
of ROS production, the variety of ROS and intracellular anti-oxidant systems that are all 
targeted by hyperglycemia-mediated derangements. 
 





Figure 1.3.2.1.1 The ETC under physiological and hyperglycemic conditions. Physiological conditions: NADH and FADH2 donate their e- 
to the ETC which transports it from complexes I to IV where it is subsequently used to reduce oxygen to water. In parallel, H+ is pumped into the 
impermeable mitochondrial intermembrane space. ATP synthase provides an outlet for the H+ to re-enter the inner membrane and subsequently 
combine ADP and Pi to yield ATP. Hyperglycemic conditions: excessive glucose breakdown leads to an increase in reducing equivalents, i.e. 
NADH and FADH2. Matching e- donation, H+ accumulate in the intramembrane space and reaches an inoperable threshold. As a result, e- cannot 
be escorted to complex III and therefore the transport protein CoQ donates excess e- to oxygen to form O·2̄ – an extremely volatile oxidizer. 
Adapted from Brownlee, 2005. 
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1.3.2.2 Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) 
While mitochondria are proposed to be the main supplier of intracellular ROS, various types 
of NOX are also implicated in the formation of oxidative species under hyperglycemic 
conditions (Syed et al., 2011). NADPH oxidase catalyzes the reduction of O2 to O·2̄ by 
simultaneously oxidizing NADPH to NADP+ (Pircher et al., 2016). For this reason it is proposed 
to function as an oxygen sensor that participates in intracellular signaling. However, when 
hyperglycemia ensues this role is obscured by excessive ROS production (Syed et al., 2011). 
How does NOX activation contribute to detrimental outcomes? Syed and colleagues (2011) 
proposed a possible mechanism where NOX initiates mitochondrial dysfunction and apoptosis 
in pancreatic –cells by upregulating ROS to such an extent that it triggers c-Jun N-terminal 
kinases activation (a pathway activated by stress). The pancreatic β-cells subsequently 
undergo apoptosis and decompensation when a critical impairment is reached. This proposed 
mechanism has since been partly corroborated by the same group which showed that ROS 
generation and downstream mitochondrial damage is indeed mediated by NOX (Kumar et al., 
2015). NADPH oxidase activity also plays a role in mediating hyperglycemic damage in the 
heart (Balteau et al., 2011; Zhang et al., 2006; Santos et al., 2011). For example, our 
laboratory found that acute hyperglycemia stimulated the production of a small amount of 
mitochondrial ROS in rat heart cells that resulted in downstream effects such as NOX 
activation (Joseph et al., 2014). The initial mitochondrial ‟trigger” ROS is thought to stimulate 
a downstream cascade of more NOX-dependent ROS production that culminates in reduced 
insulin action in these cells.  
1.3.2.3 Other sources and species of ROS 
Various other sources also promote ROS formation under hyperglycemic conditions, including 
xanthine oxidase, glucose autoxidation, peroxynitrite (ONOO-), uncoupled endothelial nitric 
oxide synthase (eNOS) and cytochrome p450. Hypoxanthine is converted to xanthine and 
subsequently to uric acid with xanthine oxidase acting as the catalytic enzyme (reviewed in 
Singh et al., 2009). A by-product of this reaction is O·̄2 which is subsequently converted to 




hydrogen peroxide (H2O2) and hydroxyl radicals (OH·̄) (reviewed in Szkudelski, 2001). There 
is an increase in xanthine oxidase activity in diabetic persons and a parallel increase in 
radicals that oxidize molecules they encounter (Desco et al., 2002). With hyperglycemia there 
is also a concomitant increase in O·̄2 and nitric oxide (NO) (Cosentino et al., 1997) and the 
reaction of these two molecules form ONOO-, an extremely reactive oxidizing agent that can 
cause significant cellular damage (reviewed in Ceriello et al., 2002). Peroxynitrite can also 
uncouple eNOS which causes a further increase in O·̄2 (reviewed in Kayama et al., 2015; 
Satoh et al., 2005). Such ROS described are considered dangerous due to their volatile nature 
and ‟reactive” oxidizing agents that can interact with DNA, lipids and, proteins to thereby 
modify their functional and structural characteristics. Such macromolecules are then unable 
to perform their physiological function and are considered hazardous to their immediate 
cellular environment. 
In summary, various cellular mechanisms contribute to ROS formation which can lead to ROS-
induced damage and modifications of macromolecules. This causes an impairment of their 
respective physiological functioning and thereby leading to organelle and cellular dysfunction. 
However, under physiological conditions the oxidative balance can be restored as cells 
possess inherent anti-oxidant mechanisms that help neutralize oxidative species and thereby 
serve in a protective capacity against oxidative stress.  
1.3.3 Intracellular anti-oxidant mechanisms  
Cells possess various anti-oxidant mechanisms that safeguard against oxidative damage due 
to excessive ROS production (Figure 1.3.3.1). Here superoxide dismutase (SOD), catalase 
and glutathione are a few of the anti-oxidant systems that cells have available in their defense 
arsenal. Superoxide dismutase converts O·2̄ (an extremely reactive oxidant) to H2O2, a lesser 
reactive species which is subsequently metabolized by catalase to H2O and O2. Glutathione 
peroxidase is also able to sequester H2O2 by employing reduced glutathione (GSH) as e- donor 
to produce H2O and oxidized glutathione (GSSG). The latter is recycled by glutathione 




reductase - a NADPH- dependent enzyme- to replenish GSH levels (reviewed in Münzel et 
al., 2017). 
 
Figure 1.3.3.1 Intracellular anti-oxidant systems that guard against oxidative stress. 
Various sources contribute to ROS formation. Superoxide is an oxygen radical that is 
extremely unstable. Several anti-oxidant mechanisms serve as protective measures against 
O·2̄. For example, SOD is able to dismutate O2- to H2O2, which is a less reactive oxidizer. H2O2 
can subsequently be converted to H2O and O2 by catalase or it can enter the glutathione 
recycling pathway. Here glutathione peroxidase catalyzes the conversion of GSH and H2O2 to 
GSSG and H2O, whereafter glutathione reductase uses NADPH to reduce GSSG to GSH. 
 
Under pathophysiological circumstances such as diabetes, endogenous anti-oxidant systems 
often fail as they cannot compensate for cumulative ROS. When this occurs the homeostatic 
redox balance is disrupted and oxidative-mediated stress occurs - mechanisms discussed 
below. It is necessary to point out here that reactive oxygen and –nitrogen species have a 
physiological role and that impaired functioning occurs as a result of hyperglycemic conditions. 
1.3.4 Hyperglycemia and ROS enhances flux through metabolic circuits 
As discussed, hyperglycemia triggers mitochondrial O·2̄-production that results in PARP 
activation and the accumulation of upstream glucose metabolites (reviewed in Brownlee, 2005 
and refer Section 1.3.2.1 above). Accumulated glucose intermediates such as glyceraldehyde-




3-phosphate (G3P) can activate the AGE pathway and the PKC pathway, while glucose and 
fructose 6-phosphate (F6P) are shunted into the polyol pathway and the HBP, respectively 
(Figure 1.3.4.1) (reviewed in Brownlee, 2005; reviewed in Zhang, 2014). Each of these 
pathways can in their own way contribute to ROS and oxidative stress, either via the 
production of oxidative species or by consuming anti-oxidants. 
1.3.4.1 Advanced Glycation End-products  
Glycation is the irreversible, enzyme-independent modification of proteins and lipids as it 
reacts with aldose sugars, which result in the formation of AGEs (Schmidt et al., 1994; 
Natalizio et al., 2001). The sources of AGEs are plenty, as multiple pathways are responsible 
for its formation and also for some pathway intermediates (reviewed in Forbes et al., 2005). 
Here pathways include the Wolff pathway where glucose self-oxidizes, the Namiki pathway 
where Schiff bases are formed, and the Hodge pathway which produces Amadori products 
(reviewed in Baynes and Thorpe, 1999; reviewed in Mapanga and Essop, 2016). All these 
pathways converge to form reactive dicarbonyls that are well-known AGE intermediates 
(reviewed in Mapanga and Essop 2016).  
Advanced glycation end products contribute to ROS formation in three main ways. Firstly, the 
process by which AGE are formed generates free radicals (Yim et al., 2001). Secondly, the 
interaction of AGEs and their receptors (RAGE) can activate pathways such as nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) that are also involved in ROS 
formation (Schmidt et al., 1994). Lastly, their modification of molecules – specifically anti-
oxidants – can result in dysfunction (Kawamura et al., 1992; Morgan et al., 2002). 
1.3.4.2 Polyol pathway 
About 3% of glucose-6-phosphate (G6P) enters the polyol pathway under physiological 
conditions (Morrison et al., 1970). However, under hyperglycemic conditions this figure 
increases by more than tenfold (González et al., 1984). The conversion of glucose to sorbitol 
is catalyzed by aldose reductase where NADPH (enzyme cofactor) is oxidized to NADP+ 
(González et al., 1984). The regeneration of NADPH consumes GSH, the most abundant 




natural anti-oxidant (Shakeel, 2015). Thus increased polyol pathway flux indirectly depletes 
GSH which in turn leads to increased intracellular ROS levels. 
1.3.4.3 Protein kinase C 
Protein kinase C belongs to a family of protein kinases involved in various signaling pathways 
(Newton, 2003). No less than eleven PKC isoforms are known to date and these are 
categorized into classical-, new-, and atypical PKCs according to their structure and 
dependence on calcium (Ca2+) (reviewed in Koya and King, 1998). Hyperglycemia causes the 
activation of some conventional PKC isoforms (i.e. β, δ, and α) via the induction of 
diacylglycerol (Inoguchi et al., 2000). Subsequently, PKC forms ROS via the upregulation of 
NOX which in turn stimulates O·2̄ production (refer Section 1.3.2.1 and 1.3.2.2).  
1.3.4.4 Hexosamine biosynthetic pathway 
Under physiological conditions, the HBP functions as a nutrient sensing pathway (especially 
glucose) and produces uridine diphosphate-N-acetyl glucosamine (UDP-GlcNAc) (Rajapakse 
et al., 2008). Further processing of UDP-GlcNAc results in the transfer of O-linked β-N-
acetylglucosamine moieties to side chains of target proteins or lipids (reviewed in Hardiville 
and Hart, 2014). Hyperglycemia induces increased flux through this pathway due to increased 
availability of substrates and this has also been linked to ROS formation as well as diabetes-
related complications such as insulin resistance, pancreatic β-cell dysfunction and cardiac-
specific damage (reviewed in Garson et al., 2014; Rajapakse et al., 2008). 





Figure 1.3.4.1 Glycolytic metabolites enter NOGPs. Hyperglycemia leads to increased 
intracellular glucose availability. The most common pathway for glucose breakdown is via 
anaerobic glycolysis. With increased glycolysis, there is a concomitant upsurge in 
mitochondrial ROS which leads to DNA damage. PARP is activated to repair DNA damage, 
but this inhibits the glycolytic enzyme GAPDH. Non-oxidative glucose pathway flux is 
enhanced to help clear the build-up of intracellular glucose metabolites. However, 
hyperactivation of NOGPs leads to increased ROS production with damaging outcomes. This 
forms a vicious cycle of ROS-induced-ROS where excessive ROS can further activate the 
NOGPs. 
  




Hyperglycemia-mediated ROS can lead to glucose toxicity or ‟glucotoxicity” as it can lead to 
several downstream effects including cell death (Giacco and Brownlee, 2010). Glucotoxicity 
can also be facilitated by other cellular stresses that include endoplasmic reticulum stress and 
mitochondrial stress, and cross-talk between such systems (Mooradian, 2016). 
As described previously (refer Sections 1.3.2 to 1.3.3), it is evident that oxidative stress plays 
a mechanistic role in hyperglycemia-induced damage. Oxidative stress can also exacerbate 
hyperglycemia-mediated effects by contributing to diabetes-related complications such as 
insulin resistance, glucotoxicity, and pancreatic β-cell dysfunction. Moreover, various positive 
feedback cycles exist such as ROS-inducing-ROS, where mitochondrial O·2̄ can lead to the 
activation of metabolic circuits (NOGPs) that themselves increase ROS generation. NADPH 
oxidase also generates O·2̄ that can further fuel NOGP activation. As such mechanisms are 
interlinked, this complicates the advance of therapeutic options to alleviate and salvage 
hyperglycemia-induced organ and cellular damage. In the next section, we will discuss the 
effect of hyperglycemia and hyperglycemia-induced oxidative damage on particular organs of 
interest to this study. 
1.3.5 Effect of hyperglycemia and downstream oxidative stress on the heart, liver, and 
circulation  
Hyperglycemia affects many tissues, but the extent to which damage is caused is often tissue- 
or even cell-specific. It is with this rationale in mind that we next discuss the effects of 
hyperglycemia and hyperglycemia-induced oxidative stress on specific organs of interest to 
this study. 
1.3.5.1 Effect of hyperglycemia and downstream oxidative stress on the heart 
When the heart is subjected to chronic hyperglycemia, metabolic perturbations are often 
encountered. Here oxidative stress is induced by all the previously described mechanisms – 
increased mitochondrial O·2̄ production, surplus flux via NOGPs, as well as NOX hyperactivity 
and decreased anti-oxidant defense capacity. Extensive ROS accumulation can impact on the 
mitochondrial ETC, causing hyperpolarization of the inner mitochondrial membrane as 




discussed (reviewed in Brownlee, 2005). This can trigger mitochondrial permeability transition 
pore (mPTP) opening (attempting to equilibrate membrane ionic imbalances), leading to the 
accumulation of intracellular Ca2+ (Baines, 2009). 
Cardiomyocytes are especially vulnerable to mitochondrial dysfunction and subsequent Ca2+ 
dysregulation as they are particularly rich in mitochondrial content to match energy demands 
to sustainably perform its ATP-intensive function (Page and McCallister, 1973). Moreover, 
Ca2+ is highly regulated by the sarcoplasmic reticulum and governs cardiomyocyte contraction 
(reviewed in Stammers et al., 2015). Altered Ca2+ homeostasis can impede cardiac 
functionality and induce maladaptive cardiac remodeling as it is centrally involved in signaling 
pathways (reviewed in Berridge et al., 2000; reviewed in Berridge et al., 2003). 
Besides damaging DNA, oxidative species are also known to react with macromolecules such 
as lipids and protein. For example, cardiolipin is a mitochondrial membrane constituent that is 
often a casualty of increased intracellular ROS levels (reviewed in Circu and Aw, 2010). Due 
to the large mitochondrial capacity of cardiac tissues, cardiolipin oxidation renders the heart 
especially vulnerable to oxidative damage and subsequent cell death via apoptosis. Similarly, 
a disproportionate amount of ROS can initiate protein unfolding, carbonylation, and oxidation 
that can prompt apoptosis (reviewed in Berlett and Stadtman, 1997; reviewed in Suzuki et al., 
2011). 
Hyperglycemia-induced oxidative stress can also initiate myocardial insulin resistance via the 
induction of mitochondrial dysfunction and NOGP activation. Data from our laboratory 
demonstrate that NOGP stimulation elicits impaired GLUT-4 translocation in rat heart cells 
(Joseph et al., 2014). Moreover, our laboratory also found that acute hyperglycemia resulted 
in hyperglycemia-mediated oxidative stress and NOGP activation that subsequently 
diminished the contractile function of ex vivo perfused hearts (Mapanga et al., 2014). 
Collectively these data show that the heart is susceptible to oxidative stress within the context 
of hyperglycemia. 




1.3.5.2 Effects of hyperglycemia-induced oxidative stress on the liver  
The liver plays a central role in metabolism as it acts as an energy-substrate ‟manufacturer 
and distributor” for the rest of the body. As a result of this crucial role, the liver is exposed to 
continual oxidative stress and therefore needs an arsenal of anti-oxidant capacity. The latter 
is linked to fuel substrate availability, e.g. diabetic individuals can display increased blood 
glucose concentrations due to greater hepatic glucose uptake (Efendίc et al., 1985). Together 
with amplified glycogenolysis and gluconeogenesis it increases hepatic glucose production 
that contributes to systemically elevated glucose levels (Magnusson et al., 1992). The 
metabolism of the liver is thus increased, leading to greater ROS generation. 
Hepatocyte mitochondria are strongly implicated in this process within the diabetic context. 
Such effects seem to be due to hyperglycemia per se as similar results were found for both 
T1DM and T2DM. Thus mitochondrial dysfunction and particularly diminished oxidative and 
phosphorylative activities, increased oxidative stress and a depleted anti-oxidant defenses are 
significant hyperglycemia-mediated outcomes in liver cells (reviewed in Dey and 
Swaminathan, 2010). 
The most prevalent mechanisms that contribute to excessive hyperglycemia-induced hepatic 
ROS are lipid peroxidation and protein carbonylation (Jang et al., 2000; Lukivskaya et al., 
2007). Lipid peroxidation, as measured by thiobutyric acid reactive substances (TBARS), can 
lead to inflammation and further damage (Dias et al., 2005). With increased ROS, there is a 
parallel decrease in anti-oxidant systems, particularly GSH and the mitochondria-specific form 
of SOD – manganese (Mn)-SOD (Jang et al., 2000). 
It is interesting to note that the mitigation of hyperglycemia-induced oxidative stress (protein 
carbonylation) partially rescued mitochondrial function irrespective of mitochondrial enzyme 
activity (Lukivskaya et al., 2007). It is still unclear whether mitochondrial dysfunction is a cause 
or result of oxidative stress; however, it is more likely that it is one of the various mechanisms 
that contribute to ROS formation and hepatocyte dysfunction.  




1.3.5.3 Effects of hyperglycemia-induced oxidative stress in circulation 
Unlike biopsies of the heart and liver, blood samples are relatively easy to obtain as it can be 
collected with minimal invasiveness. This has allowed researchers the ability to assess the 
oxidative status of individuals with diabetes. Here data show that individuals who suffer from 
T1DM display advanced levels of lipid peroxidation (TBARS) as measured in plasma and 
erythrocytes (Matteucci and Giampietro, 2000). Moreover, non-diabetic siblings of such 
individuals also exhibited significantly more lipid peroxidation compared to controls. However, 
anti-oxidant defenses (GSH) were only diminished in the diabetic cohort. 
Erythrocytes and other blood constituents are susceptible to modifications that alter their 
characteristics and functions (Olszewska et al., 2012; Wautier et al., 1994). For example, 
erythrocytes from diabetic patients are often glycated and this is used as one of the diagnostic 
markers of this metabolic disease (Table 2). The glycation of erythrocytes allows for interaction 
with RAGE and subsequently induce oxidative stress in other targets such as endothelial cells 
(Wautier et al., 1994). This in turn increases the risk of developing atherosclerosis and 
cardiovascular diseases. 
To summarize, hyperglycemia induces ROS formation which (if not neutralized effectively) 
causes oxidative stress and subsequent damage. Moreover, increased ROS levels can 
enhance NOGP activation that in turn leads to more ROS formation and NOGP-induced 
damage. The focus will now shift to a NOGP of high relevance for the current study, i.e. the 
pentose phosphate pathway (PPP). 
1.4 Pentose Phosphate pathway  
The PPP provides an alternate path for glucose intermediates and serves two other important 
functions, namely NADPH production (reducing equivalent used for anabolic reactions and 
replenishment of GSH) and the generation of ribose-5-phosphate (R5P) (used for nucleotide 
biosynthesis). 




The PPP consists of two parts, the oxidative and the non-oxidative branches (Figure 1.4.1) 
(Horecker, 1964; Srivastava and Hübscher, 1966). In the oxidative branch G6P undergoes 
three irreversible reactions of which glucose-6-phosphate dehydrogenase (G6PD) catalyzes 
the rate-limiting step. These reactions yield NADPH, a reducing equivalent for lipid 
biosynthesis as well as anti-oxidant defense, and ribulose-5-phosphate (Ru5P) (reviewed in 
Patra and Hay, 2014). Subsequently, Ru5P enters the reversible non-oxidative branch where 
it can be converted to R5P or xylulose-5-phosphate (X5P, glycolytic intermediates) (reviewed 
in Riganti et al., 2012). The flux-controlling enzymes of the non-oxidative phase, 
transketolases (TKTs) are able to recycle such pentose phosphate products back into PPP or 
into glycolysis (Berthon et al., 1992; Gumaa et al., 1969; Schenk et al., 1998; Srivastava and 
Hübscher, 1966). 
The glycolytic pathway consists of two phases: an ‟investment phase” that consumes ATP, 
and the ‟payoff phase” that produces ATP (Figure 1.4.1). Glyceraldehyde-3-phosphate is one 
of the products that is recycled into glycolysis and enters this pathway at the beginning of the 
payoff phase. This means that G6P can enter the PPP and enhance anti-oxidant defenses, 
produce substrates for nucleotide synthesis and be used as a substrate for ATP production. 
Moreover, F6P can be reversibly converted back to G6P and can re-enter the PPP and thereby 
facilitate more NADPH formation. 
Of note, some of the initial work on the PPP was conducted on human erythrocytes (Strömme 
and Eldjarn, 1962; Szeinberg and Marks, 1961). Here it was established that hemolytic anemia 
correlated with deficient GSH due to insufficient PPP activity that renders the erythrocytes 
vulnerable to oxidation (reviewed in Patra and Hay, 2014). This highlighted the significant role 
of the PPP in redox homeostasis as the replenishment of GSH relies solely on NADPH – a 
by-product of the PPP (Mayes, 1993). As the PPP and glycolysis are interlinked, it stands to 
reason that hyperglycemia will have a tremendous effect on the PPP. 
.




Figure 1.4.1 Pentose phosphate pathway. Glucose-6-phosphate passes through the oxidative phase of the PPP where it is converted to Ru5P 
and pentose phosphates (X5P and R5P). The latter can exit the PPP to enter nucleotide biosynthesis or continue through the PPP – the non-
oxidative branch. Here transketolase enzymes (TKT, TKTL1, TKTL2) governs two reversible reactions namely, the conversion of X5P and Ru5P 
to G3P and sedoheptulose 7-phosphate, and erythrocyte 4-phosphate and X5P to F6P and G3P, respectively. Transaldolase catalyzes the 
formation of F6P and erythrocyte 4-phosphate from the products of the first transketolase-catalyzed reaction. NADPH: Nicotinamide adenine 
dinucleotide phosphate, GSH: reduced glutathione, GSSG: oxidized glutathione, TKT: transketolase, TKTL1: TKT-like 1, TKTL2: TKT-like 2, ATP: 
Adenosine triphosphate. Adapted from Joseph, 2014 and Schenck et al., 1998. 
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1.4.1 Effect of hyperglycemia on the PPP 
What happens to the PPP in response to hyperglycemia/diabetes? Here data have been 
somewhat controversial as evidence for an increase and a decrease in activity has been 
reported (Gamaa et al., 1969; Leroux et al., 1975; Novello et al., 1969). It should be noted that 
the response of the PPP seems to be tissue-specific which may help explain such disparate 
findings. Considering the harmful effects of hyperglycemia (refer Sections 1.3.3 and 1.3.4), it 
stands to reason that enhanced PPP flux should allow for replenishment of intracellular anti-
oxidant defenses, promote nucleotide and lipid biosynthesis and also provide metabolic 
substrates for ATP generation. Moreover, it is a generally accepted notion that favoring PPP 
flux shunts glycolytic intermediates away from damaging NOGPs and thereby providing 
additional beneficial effects (Du et al., 2008; Joseph et al., 2014; Katare et al., 2010). 
1.4.2 Enhancing flux via the PPP and benefits  
Pentose phosphate pathway activation can be achieved by supplementation with derivatives 
of vitamin B1, thiamine or benfotiamine [BFT], with the latter displaying superior bioavailability 
compared to the former (reviewed in Garson et al., 2014). Benfotiamine is a lipid-soluble 
derivative proposed to elicit various health-promoting effects as it acts as an anti-oxidant, anti-
inflammatory and cardio-protective agent (Shoeb and Ramana, 2012; Katare et al., 2010; 
Schmid et al., 2008). Both thiamine and BFT enhance PPP flux as they act as cofactors for 
TKT thereby increasing its activity (Joseph and Essop, 2014). 
Studies employing BFT found that PPP induction can prevent NOGP activation, including the 
HBP, advanced glycation, and PKC activation and thereby alleviated diabetic retinopathy 
(Hammes et al., 2003). BFT supplementation also diminished NF-κB activation (a key 
regulator of inflammation) and protected against the onset of diabetic nephropathy (Babaei-
Jadidi et al., 2003). It also protects against micro- and macrovascular impairment, most likely 
through the inhibition of AGEs (Stirban et al., 2006). In cardiac progenitor cells of diabetic 
patients the clearance of AGEs and other oxidative species is upregulated by BFT, leading to 




increased cell survival (Katare et al., 2013). Notably, thiamine and its beneficial effects arise 
from the activation of the non-oxidative branch of the PPP which is governed by TKT (Joseph 
and Essop, 2014). In view of the protective effects of TKT per se, and as it forms the basis of 
this study, we next discuss this enzyme family in more depth. 
1.5 The transketolases 
Transketolases are enzymes that catalyze the reversible transfer of ketol groups from a ketose 
to an aldose with thiamine and divalent cations as cofactors (Abedinia et al., 1992; Berthon et 
al., 1992; Clark and Williams, 1971; Meloche, 1964; Nikkola et al., 1994; Traviesa, 1974). The 
TKT family include TKT and two TKT-like genes (TKTL1 and TKTL2) that play an integral part 
in several facets of metabolism including possibly contributing to total TKT (tTKT) activity (Coy 
et al., 2005). The reason for this is that TKTs (and to a lesser extent transaldolases) are the 
flux-controlling enzymes of the non-oxidative branch of the PPP (Berthon et al., 1992; Schenk 
et al., 1998). 
1.5.1 Transketolase structure 
Around four decades after its discovery, both the purification and the partial sequencing of 
human TKT were completed (Abedinia et al., 1992). Here it was shown that this roughly 70 
kDa homodimer displays a relatively high sequence similarity to associated enzymes in other 
species such as Hansenula polymorpha and Rhodobacter sphaeroides. Each of the identical 
subunits possesses three domains namely an amine (N)-terminal pyrophosphate (PP)-
domain, a pyrimidine-binding (Pyr) domain, and a carboxy (C)-terminal domain (Lindqvist et 
al., 1992). Both the PP-domain and the Pyr domain are involved in dimerization and cofactor 
binding, while the function of the C-terminal domain remains to be determined (Schneider et 
al., 1998). The complete structural resolution of human TKT was achieved during 2010 (Figure 
1.5.1.1) (Mitschke et al., 2010). This allowed for the sequence alignment of TKT among 
several different species that included microorganisms, plants, and animals and revealed 
several interesting findings. 




First, the three-dimensional structure of human TKT is conserved among species. It consists 
of two homodimers which rely on thiamine diphosphate (TDP) and Ca2+ to perform its function 
(Mitschke et al., 2010). Second, the researchers noted that the substrate channel of 
mammalian TKT is more tapered compared to other TKTs, which provides an explanation why 
the substrate range of mammalian TKT is limited compared to that of lower organisms. Lastly, 
although there are multiple point mutations, the overall function of the enzyme seems to be 
well conserved. This suggests that TKT provides an evolutionary advantage which seems to 
have become more specialized over time. Although the substrates of TKT differ among 
species, mammalian TKT catalyzes reactions of only four substrates as shown in Figure 
1.5.1.2 (modified from Schenck et al., 1998).  
 
Figure 1.5.1.1 Structure of human transketolase. A: 3-dimensional (3D) model of human 
transketolase holodimer with TDP and Ca2+ cofactors. B: Rotated 3D model of human TKT. 
C: Thiamine bound to TKT. Cyan & magenta: TKT subunits, blue spheres: Na+, grey spheres: 
Ca2+.Image created with iCn3D: The Structure Of Human Transketolase (PDB ID 3MOS). 





Figure 1.5.1.2 Reactions catalyzed by human transketolase (modified from Schenck et al., 
1998). 
 
1.5.1.1 Interaction of transketolase with its cofactor – thiamine diphosphate 
Like all other thiamine-dependent enzymes, the binding site for thiamine diphosphate lies in a 
deep crevice at the interface of the dimer (Muller et al., 1993). Here TDP enters the binding 
site to form a TKT-TDP intermediate. Thereafter, TDP causes several conformational changes 
in the enzyme. This allows the PP domain of one subunit to attach to the diphosphate group, 
while the Pyr domain of the other subunit fastens the aminopyrimidine ring (Schneider et al., 
1998). Thus TKT is activated only when TDP binds to and causes conformational changes in 
the apoenzyme, thereby completing the catalytically active holodimer. 
1.5.1.2 Transketolase activity 
The evidence concerning the evolutionary conservation of TKT is plentiful (Burrai et al., 2017; 
Schenk et al., 1998; reviewed in Zhao and Zhong, 2009). This supports the notion that TKT 
activity is fundamental in the maintenance and expansion of life. The earliest mention of TKT 
activity dates to the 1950s (reviewed in Kochetov and Solovjeva, 2014) and it gained further 
interest when decreased TKT activity was implicated in various pathologies, including Beriberi 
and Wernicke-Korsakoff encephalopathy (Gibson et al., 1988; Leigh et al., 1981; McCandless 
et al., 1968; Saito et al., 1987; Sheu et al., 1988; Traviesa, 1974; Wang et al., 1997). It was in 




the undertaking to determine the mechanism behind such pathologies that the biological 
function of this enzyme was eventually elucidated. 
Decreased TKT activity due to a deficiency of thiamine and/or magnesium was initially 
investigated for a causal role in several neurological disorders – most prominently Wernicke-
Korsakoff encephalopathy and Alzheimer’s disease (Gibson et al., 1988; Leigh et al., 1981; 
Sheu et al., 1988; Traviesa et al., 1974; Wang et al., 1997). More relevant to the context of 
the current study, decreased TKT activity was also linked to metabolic disturbances such as 
diabetes and related complications (Saito et al., 1987). This suggests that there is a minimum 
required level of TKT activity that, if not sustained, can lead to neurological and/or metabolic 
disorders (McCandless et al., 1968). As diabetes is a fundamental part of this study, the focus 
will shift to what is known about TKT in this particular context. 
1.5.1.3 Transketolase in diabetes 
Various studies employed an established STZ-induced diabetes model to gain further insights 
into this question (Furman, 2015; Katare et al., 2010; Mapanga et al., 2014). For example, 
decreased thiamine concentrations and TKT expression/activity could be ameliorated by BFT 
or thiamine treatment of STZ-treated rats (Babaei-Jadida et al., 2003). Such treatment also 
prevented nephropathy which the authors attributed to the induction of TKT expression that 
presumably decreases flux through several NOGPs. Thus hyperglycemia-mediated damaging 
effects (discussed earlier) can be ameliorated by increasing TKT activity through the intake of 
thiamine. In support, others showed that BFT oral supplementation lowered diabetes-related 
complications (Du et al., 2008; Hammes et al., 2003). These studies concluded that such 
protection was achieved via the increase of TKT activity, thereby favoring PPP flux versus the 
other more harmful NOGPs. 
Such evidence is also corroborated by studies recently performed in our research group using 
an in vitro model of hyperglycemia (Figure 1.5.1.3.1) (Joseph, 2014). Here rat heart cells 
subjected to simulated hyperglycemia showed increased NOGP activation which could be 
reversed with BFT treatment. Likewise, another study that employed the rodent STZ-induced 




diabetes model demonstrated that BFT treatment alleviated oxidative stress and decreased 
diabetes-induced damage (Wu and Ren, 2006). 
Although not concluded by the authors, the results show that there is an increase in the 
GSH:GSSG ratio which indicates that the protective effect may be directly or indirectly 
attributable to PPP activation. Others showed that the use of BFT as TKT activator prevented 
STZ-induced vascular endothelial dysfunction and nephropathy by diminishing pathological 
changes in glomeruli and reducing oxidative stress (Balakumar et al., 2009). However, the 
protective effects of TKT activation are not only limited to the clinical context of nephropathy. 
 
Figure 1.5.1.3.1 BFT reverses hyperglycemia-induced NOGP activation. In this in vitro 
model (rat heart cells) of simulated hyperglycemia (25 mM glucose for 24h), BFT (100 µM) 
reverses NOGP activity while concurrently activating the PPP. (Joseph, 2014). 
 
For example, BFT treatment improved post-ischemic recovery in STZ-diabetic mice by 
favoring survival pathways (Gadau et al., 2006), while others found it also ameliorated 
diabetes-induced cardiac dysfunction (Ceylan-Isik et al., 2006). The inhibition of TKT activity 
by oxythiamine (a thiamine derivative and irreversible inhibitor of TKT) can induce apoptosis 
and also inhibit cell proliferation by reducing nucleotide and NADPH availability (Burrai et al., 
2017). Notably, studies from our laboratory concluded that BFT induces activation of TKT per 
se, as G6PD activity remained unaltered (Figure 1.5.1.3.2) upon BFT treatment (Joseph et al., 
2014). 





Figure 1.5.1.3.2 BFT activates PPP in an in vitro model of hyperglycemia. Treatment with 
BFT (100 µM) induces PPP flux by increasing transketolase activity rather than affecting G6PD 
activity (Joseph et al., 2014). 
 
Data from our research group also demonstrate that TKT expression is unaffected in pre-
diabetic and diabetic subjects but that this is not the case for TKTL1 which shows a stepwise 
increase in its expression (Figure 1.5.1.3.3). In light of this intriguing finding, our group has 
focused its efforts on understanding the role of TKTL1 within the diabetic context. This MSc 
study forms part of this broader initiative and the available literature concerning TKTL1 will 
next be reviewed. 
 
Figure 1.5.1.3.3 Expression patterns of transketolase and TKTL1 in leukocytes of 
control, pre-diabetic, and diabetic patients. Expression normalized to β-actin (Coomer and 
Essop, unpublished data).  




1.5.2 Transketolase-like 1 (TKTL1) 
1.5.2.1 TKTL1 Structure and activity 
Initially named TKT related-gene, TKTL1 was first discovered in 1996 (Coy et al., 1996). Here 
different tissue isotypes were identified and the authors suggested that this points to tissue-
specific functions. Some key differences between transketolase and TKTL1 include a deletion 
of 47 amino acids that is assumed to interfere with the active site and a 38 amino acid deletion 
that contains residues involved in cofactor binding (Schneider et al., 2012). However, it was 
proposed that this enzyme might act as a regulator of TKT activity irrespective of differences 
compared to TKT (Coy et al., 2005). A haploinsufficiency model of TKT in mice prompted the 
question whether or not TKTL1 itself possesses TKT activity (Xu et al., 2002). This is because 
TKTL1 exhibited no compensation for TKT loss which was as much as 50% in the testes – 
where TKTL1 is generally overexpressed. Almost a decade after its discovery, further research 
into this enzyme revealed that it may not only possess the expected TKT activity but it was 
also hypothesized to catalyze a unique one-substrate reaction (Coy et al., 2005). This together 
with its specific localization (nuclear and cytosolic) indicates that the function of TKTL1 is likely 
multifactorial. Moreover, a striking association between TKTL1 expression and aerobic 
glycolysis (Warburg effect) was revealed. Thus began the strong association between TKTL1 
and cancer (refer Section 1.5.2.2). 
There are several articles that explored the nature of TKTL1 activity, with some stating that it 
has no function due to the 38 amino acid deletion, while others claim that it does indeed 
contribute to TKT activity. Here an important consideration is that insights regarding TKT 
activity up to that point were based on the assumption that it involved only one enzyme (Coy 
et al., 2005). Various studies (refer to Table 2 below) using siRNA to inhibit TKTL1 expression 
revealed that TKTL1 plays a critical role in total TKT activity (Zhang et al., 2007; Hu et al., 
2007; Chen et al., 2009). This may either occur directly or indirectly (regulatory) as total TKT 
activity was significantly attenuated in such studies. 




By contrast, other studies reported contradictory findings by frequently inferring that TKTL1 
does not possess any TKT activity due to the aforementioned 38 amino acid deletion (Maslova 
et al., 2012; Meshalkina et al., 2013; Mitschke et al., 2010; Schneider et al., 2012). The 
comparison of TKTL1 with Saccharomyces cerevisiae TKT and human TKT showed that 
TKTL1 contains multiple mutations and/or that are critical for cofactor binding and invariant 
among other TKTs (Mitschke et al., 2010). Thus the authors concluded that TKTL1 is most 
likely incapable of TKT activity. Moreover, a computational model of TKTL1 in which the 
researchers assessed primary-, secondary-, tertiary-, and quaternary structures supported the 
work of Mitschke and co-workers (Maslova et al., 2012). Here it was concluded that TKTL1 is 
most likely to be unable to bind to thiamine and therefore not catalytically active. These 
researchers also noted that an alternative mechanism of cofactor binding, however unlikely, 
cannot be excluded. A mutant variant of TKT that accommodated the 38 amino acid deletion 
present in TKTL1 was also used to demonstrate that TKTL1 is devoid of TKT activity 
(Meshalkina et al., 2013). Of note, such studies based their conclusions on the inability of 
TKTL1 to bind to its cofactor. 
A recent study from our group employed homology modeling and structural analysis of the 
human TKT family combined with a thiamine cofactor to further investigate this contentious 
matter (Deshpande et al., submitted). Here it was demonstrated that TKTL1 binding to its 
cofactor is indeed plausible (Figure 1.5.2.1.1). 





Figure 1.5.2.1.1 Homology of TKTL1 based on the transketolase co-crystal structure 
with thiamine diphosphate-D-xylulose-5-phosphate adduct. A) Ribbon representation of 
the homodimer (tan and blue sub-units) of TKT with the TDP-X5P adduct ligand shown as red 
spheres. The 1, ɑ4 and 2 helices (green), as well as H77 and H110 (yellow) (absent in 
TKTL1), are shown. (B) Homology model of TKTL1 shown as a homodimer (tan and blue sub-
units) and fitted to the coordinates of TKT to show the location of the substrate adduct, 
indicated by the red spheres. (C) The ligand present in the substrate cleft that is formed 
between the surfaces of the two units in the TKT homodimer is shown. (D) A similar substrate 
cleft is visible between the two units of the homodimer in the homology model of TKTL1. (E) 
A di-phosphate binding cavity is visible on the surface within the substrate cleft of each 
monomer in the TKT homodimer. (F) A di-phosphate binding cavity is also visible within the 
substrate cleft of the TKTL1 homology model. (Deshpande et al., submitted). 
 
This structural model of TKTL1 in conjunction with two recent publications from different 
laboratories that employed radio-labeling experiments now provide useful insights into the 
intricate workings of TKTL1. Here Diaz-Moralli and colleagues (2016) demonstrated that 
TKTL1 catalyzes TKT reactions in the non-oxidative branch of the PPP and thus contributes 
to total TKT activity. Moreover, a unique role for TKTL1 in fatty acid metabolism was revealed, 
with lipid synthesis proposed to occur due to a TKTL1-catalyzed one-substrate (X5P) reaction 
with G3P and acetyl coenzyme A (acetyl-CoA) as products. The latter can be used for the 
biosynthesis of lipids. Similarly, others provided evidence of significant TKTL1 flux in Chinese 




hamster ovary cells that were previously shown to possess increased total TKT activity (Ahn 
et al., 2016). They also presented supporting evidence for the one-substrate reaction with G3P 
and a two-carbon molecule (most likely acetyl-CoA) generated as products. To put these 
studies into context, two independent studies provided evidence that TKTL1 does indeed 
possess TKT activity and that it can also catalyze a unique one-substrate reaction. These two 
factors may help explain the notorious advantage that TKTL1 is proposed to offer various 
cancers.  
1.5.2.2 TKTL1 in cancer 
As the literature on TKTL1 is predominated by its role in cancer (refer Tables 1.5.2.2.1 and 
1.5.2.2.2), it is necessary to consider contemporary thoughts on the matter. The Warburg 
effect explains the altered metabolism by cancer cells where there is a robust upregulation of 
aerobic glycolysis (reviewed Liberti and Locasale, 2016). Here TKT mediates the upregulation 
of non-oxidative glucose metabolism and has therefore been implicated in the development 
and migration of cancer (Figure 1.5.2.2.1) (Chao et al., 2016; Rais et al., 1999; Upadhyay et 
al., 2013). However, expression of TKTL1 (but not TKT or TKTL2) is elevated in various types 
of cancers (reviewed in Sun et al., 2010). This suggests that TKTL1 could play an integral role 
in the governing processes of cancer cells and may offer some insights on the function of this 
enzyme. Table 1.5.2.1.1 (below) summarizes some of the literature on the manipulation of 
TKTL1 in various cancer cell lines. Taken together, these findings suggests that TKTL1, 1) 
either directly or indirectly, contributes to total TKT activity, 2) assists in the survival and 
proliferation of cancer cells, and 3) may be a key regulator in the metabolic changes, such as 
increased glucose consumption and the Warburg effect, that are common characteristics of 
cancer cells.  
  




Table 1.5.2.2.1 Summary of studies manipulating TKTL1 expression in cancer cell lines 
and main findings 
TKTL1 
manipulation 
Cell line tested Main findings References 
siRNA  HepG2 (human 
liver cancer) 
▼ TKT activity 
▼ Proliferation 
Zhang et al., 
2007 
siRNA  LoVo (human 
colon cancer) 
▼ TKT activity, 
▼ Proliferation. 
Hu et al., 2007 
siRNA & shRNA  HCT116 (human 
colon carcinoma) 
▼ Glucose consumption 
▼ Lactate production 
▼ Proliferation  
▲ Sensitivity to ROS 
Xu et al., 2009 
siRNA  HeLa (human 
cervix 
adenocarcinoma) 
▼ TKT activity 
▼ Proliferation 
▲ Apoptosis 
Chen et al., 
2009 








Li et al., 2015 




▼ Glucose consumption 
▼ Lactate production 
Jayachandran 
et al., 2016 
 
The augmented expression of TKTL1 in various cancers is well documented (reviewed in 
Furuta et al., 2010; reviewed in Riganti et al., 2012). It is also proposed that TKTL1 could serve 
as a prognostic marker for cancer as its expression correlates with tumor metastasis and poor 
patient outcome (Langbein et al., 2006; Schwaab et al., 2011; Ahopelto et al., 2016). Table 
1.5.2.2.2 objectively summarizes literature on the potential role for TKTL1 as a prognostic 
marker in various cancers and highlights the major findings of these studies. 
  




Table 1.5.2.2.2 Summary of studies investigating TKTL1 expression and influence in 
cancer  








▲TKTL1, but not TKT or TKTL2 in 
cancer. 
▲TKTL1 correlates with ▲ 








Breast cancer A positive correlation between 
▲TKTL1 and ▲Her2/neu (growth-
promoting protein). 
No significant correlation between 
▲TKTL1 and poor prognosis. 








▲TKTL1 correlates with ▲ tumor 
progression, poor prognosis. 
Krockenberger 







▲TKTL1 and ▲phosphorylated-Akt 
with the histopathological grade of 
various cancers. 
Kohrenhagen 







No evidence of relevant TKTL1 
expression in malignant cell lines at 
mRNA level. 
The JFC12T10 antibody is 
questionable as it yields multiple 
bands. 











Lung cancer Expression of TKTL1 is not related 
overall survival, disease-free survival 
or any other variables in tumor 
staging system. 






▼Expression of TKTL1 as the 
disease progresses. 
Philipp et al., 
2014 




Table 1.5.2.2.2 (continued) Summary of studies investigating TKTL1 expression and 
influence in cancer 







The PPP and TKTL1 play a key role 
in tumorigenesis of MIBC. 
▲ TKTL1 in a subgroup of patients. 
No significant correlation between 
▲TKTL1 and poor prognosis. 








benign cell lines 
▲ TKTL1 expression in only two cell 
lines. 
No significant correlation between 










▲TKTL1 in melanoma tumors. 
▲ TKTL1 correlates with ▲ 
invasiveness 
Jayachandran 
et al., 2016 




A significant correlation between 
▲TKTL1 and poor prognosis. 
Ahopelto et 
al., 2016 
mRNA: messenger ribonucleic acid; IHC: immunohistochemistry, mAB: monoclonal antibody, 
ABs: antibodies RT-qPCR: reverse transcription -quantitative polymerase chain reaction, WB: 
Western blot. 
The rationale behind TKTL1 as a potential prognostic marker is that it is upregulated in various 
cancer types that have a poor prognosis. It is already known that cancer cells have 
dysregulated metabolic pathways that allow them to proliferate and grow faster than healthy 
cells. In this regard, the upregulation of TKTL1 might be one of the adaptations that is 
advantagous to cancerous cells. It is critical to understand how TKTL1 may be upregulated in 
cancer cells in order to assess whether the increased expression of this enzyme is directly 
involved and contributes to the changes in metabolism of cancer cells or if it is an independent 
factor that occurs simultaneously. It is for this reason that the focus now shifts to the regulation 
of TKTL1 and its putative role in cancer.  




Ras mutation is a common manifestation in cancer which leads to attenuated Ras-mitogen-
activated protein kinase (MAPK) signaling (reviewed in Bos, 1989; reviewed in Furuta et al., 
2010). This in turn decreases DNA methylation, causing gene promoters (e.g. TKTL1) to 
become hypomethylated (Deng et al., 1998). TKTL1 promoter hypomethylation leads to 
increased transcription and a corresponding enhancement of enzymatic activity (Sun et al., 
2010). TKTL1 activity upregulation also shows a strong association with augmented aerobic 
glycolysis, i.e. GLUT-1 facilitated glucose uptake and hypoxia-inducible factor (HIF)-1ɑ 
stabilization (reviewed in Kumar et al., 2017; Sun et al., 2010). Together such factors create 
an acidic microenvironment that facilitates tumorigenesis (Figure 1.5.2.2.1) (Langbein et al., 
2006; Sun et al., 2010). 
 
Figure 1.5.2.2.1 A role for TKTL1 in cancer.  
 




1.5.2.2.1 Advantages that TKTL1 offer in the cancer context 
Although the utilization of anaerobic glycolysis as opposed to oxidative phosphorylation may 
seem illogical due to its inefficient energy production, the exploitation of TKTL1 provides 
various benefits to cancer cells. As cancer cells have accelerated proliferative rates they need 
large amounts of energy and nucleotides to ensure rapid proliferation. Thus the one-substrate 
reaction catalyzed by TKTL1 creates the perfect opportunity to satisfy such needs: 
 Augmented metastasis facilitated by induction of acidified environment that enables 
proliferation, angiogenesis, matrix breakdown and aerobic glycolysis.  
 Acetyl-CoA (lipogenesis) and R5P (nucleotide biogenesis) that expedite tumorigenesis 
(Diaz-Moralli et al., 2016). 
 Rapid, mitochondria-independent generation of ATP. 
 Protection against oxidative damage via the provision of NADPH – a key regulator of 
redox homeostasis (Xu et al., 2009). 
1.5.2.3 TKTL1 in diabetes 
This brings us back to our research group’s focus, i.e. the role of the PPP and TKTL1 within 
the diabetic context. As discussed, data from our laboratory demonstrated that TKTL1 
expression, but not that of TKT, was higher in diabetic and prediabetic individuals. A logical 
explanation for this finding is that it occurs to help dispose of (via the PPP) the relatively high 
amounts of available glucose. This likely serves multiple purposes as the PPP serves as a 
shunt for excess glucose, produces glycolytic intermediates and also enhances antioxidant 
defenses, thereby collectively dissipating hyperglycemia and resultant damage (reviewed in 
Mapanga and Essop, 2016). Moreover, PPP upregulation can provide cardio-protection by 
attenuating glucose flux via other damaging NOGPs (discussed in Section 1.4). 
Previous work established that both total TKT activity and thiamine levels are decreased with 
diabetes (clinical and animal data) (Saito et al., 1987; Joseph and Essop, 2014). Moreover, 
there is a causal relationship between decreased vitamin B1-derivative and TKT activity, as 
treatment with thiamine and BFT (both biologically active forms of vitamin B1) successfully 




increased TKT activity. Taken together these results provide evidence that TKTL1 may be a 
significant contributor to TKT activity and reiterates its dependence on thiamine. There is also 
evidence that TKTL1 can elicit protective effects against oxidative stress which is present in 
high levels in cancer cells (Xu et al., 2009). The authors concluded that this was most likely 
due to its role as partial flux controlling enzyme of the PPP which produces NADPH necessary 
for restoring anti-oxidant defenses. 
1.6 Problem statement and hypothesis 
Considering the data presented above it is likely that TKTL1 contributes to total TKT activity. 
Apart from the conventional TKT activity, TKTL1 may possess a unique type of TKT activity 
where it catalyzes a one-substrate reaction. The combined data from our research group 
suggest that TKTL1 per se is step-wise upregulated with the progression of diabetes and that 
an increase in PPP – specifically TKT activity - may be a compensatory mechanism which 
offers protection against hyperglycemia-induced damage. However, the extent of the 
protection and the downstream mechanisms that mediate this protection remains unknown. 
Thus, we hypothesize that: 
TKTL1 plays a critical role in ameliorating intracellular oxidative stress under 
hyperglycemic conditions. 
1.7 Aim and objectives 
1.7.1 Aim 
For this project, we aimed to evaluate the putative defensive role of TKTL1 in a mouse model 
of hyperglycemia and to elucidate mechanisms underlying this process. 
1.7.2 Objectives 
 Establish an STZ-mouse model to induce hyperglycemia in wild type (WT) and TKTL1-
knock-out (KO) mice. 
 Assess the oxidative status of highly metabolic tissues (liver, heart) as well as in 
circulation. 




 Evaluate downstream effects of hyperglycemia in the aforementioned tissues. 
 Evaluate the putative protective action of TKTL1 against hyperglycemia-mediated 
oxidative stress and downstream effects thereof. 
 Assess the contribution of TKTL1 to total transketolase activity. 
 
  




Chapter 2: Materials and Methods 
2.1 Animals and ethics statement: 
For this study we aimed to elucidate the possible role of transketolase-like 1 (TKTL1) in 
oxidative stress and downstream damage in the setting of STZ-induced hyperglycemia. We 
employed a TKTL1-knock-out (TKTL1-KO) mouse model to provide a holistic approach for 
extricating the role of TKTL1. The C57BL/6-TKTL1-KO breeders (female mice) were kindly 
provided by Dr. Johannes Coy (Tavergenix GmbH, Pfungstadt, Germany) and housed and 
bred with wild type (WT) C57BL/6 male mice. Offspring were crossbred to produce TKTL1-
KO and WT littermates that were used in this study. A reversed 12h/12h day/night cycle was 
employed and animals had ad libitum access to food (standard rodent chow) and water. All 
breeding and animal procedures were carried out in the Animal Facility of the Faculty of Health 
Sciences, Stellenbosch University, Tygerberg, South Africa. 
Animals were treated in agreement with the accepted standards for the use of animals in 
research and teaching as reflected in the South African National Standards (SANS) 10386: 
2008. This study was performed with the approval of the Animal Ethics Committees of 
Stellenbosch University, Stellenbosch, South Africa (Ethics # SU-ACUD16-00052, refer 
appendix A). 
2.2 Genotyping analysis: 
Genotyping analysis was performed to identify WT and TKTL1 littermates using the KAPA 
Hotstart Fast mouse tail genotyping kit (Sigma-Aldrich, St. Louis, MO). Here, genomic DNA 
was extracted from tail cuts using the DNA extraction protocol according to the manufacturer’s 
instructions. Briefly, 2 mm sections of tail samples were added to 100 µl DNA extraction master 
mix (10X KAPA Express Extract Buffer and 1 U/µl KAPA Express Extract Enzyme diluted in 
PCR-grade water). Samples were then incubated at 75°C for 10 min followed by 95°C for 5 
min using a thermocycler. Stock DNA was transferred to fresh PCR tubes and diluted 10X with 
10 mM Tris-HCl (pH 8). The diluted DNA samples were used for genotyping PCR analysis 




with the following primer pair: 5’-ATGGCTCATGTTTCTGCTGC-3’ (forward primer – intron 3) 
and 5’-CTTGCCTTGCTTCTGTAAGG-3’ (reverse primer – intron 7) (Bentz et al. 2011). Here, 
1 µl of DNA was added to 24 µl PCR reaction master mix containing (final concentration): 1X 
KAPA 2G Fast Genotyping Mix, 0.5 µM forward primer and 0.5 µM reverse primer diluted in 
PCR-grade water. The PCR cycling protocol was set up as described in Table 2.2.1. PCR 
reaction products were subjected to 1% agarose gel electrophoresis at 120 V for 45 min. Gels 
were visualized using the Bio-Rad Chemidoc MP gel imaging system (Bio-Rad, Hercules, CA). 
With electrophoresis, TKTL1-KO resulted in a distinctive band of 338 base pairs (bp), while 
WT animals did not display any bands (Bentz et al. 2011). 
Table 2.2.1 PCR cycling protocol 
Step Temperature (°C) Time Cycles 
Initial 
denaturation 
95 3 min X1 
Denaturation 95 15 s X35 
Annealing 60 15 s X35 
Extension 72 15 s X35 
Final extension 72 1 min X1 
 
2.3 Experimental design: 
TKTL1-KO and WT mice, aged 10-12 weeks, were randomly assigned to receive either vehicle 
(0.1 M sodium citrate buffer, pH 4.5 – control groups) or STZ (40 mg/kg STZ freshly prepared 
in 0.1 M sodium citrate buffer, pH 4.5 – STZ groups) at n=10 males per group and n=5 females 
per group (refer Figure 2.3.1 A and B). Here mice were administered a single intra-peritoneal 
(i.p.) injection daily, for 5 consecutive days (Furman, 2015). The multiple low dose STZ 
protocol has previously been described and employed as it achieves hyperglycemia with 
minimized mortality. Control groups were injected with an equal volume of citrate buffer 
(according to animal weight). The welfare of all study animals was monitored and recorded 
daily. Blood glucose (tail prick, measurement with a GlucoPlus blood glucose monitoring 




system) and body weight were recorded weekly until the following criteria were met: 1) 
statistically significant higher non-fasting blood glucose levels in STZ injected groups vs. 
controls, 2) mean, non-fasting blood glucose levels ≥ 200 mg/dL (11.1 mmol/L), 3) ≥ 90% of 
animals in STZ treated group display glucose levels ≥ 11.1 mmol/L on two consecutive reading 
days (Wu and Huan, 2008; Furman, 2015). While all three criteria were satisfied in the KO 
STZ-treated group, only criterion 2 was met in the WT STZ-treated group regardless of a three 
weeks grace period in which blood glucose levels as well as hyperglycemia  incidence of the 
WT STZ-treated group plateaued (data discussed in the Results section below). As all three 
criteeria were met seven weeks after the injections, mice were terminated and organs (blood, 
heart, and liver) harvested for further analyses. This study forms part of a larger project and 
all animal handling and procedures were performed by Dr. Danzil Joseph and Ms. Natasha 
Driescher under the guidance and supervision of Mr. Noel Markgraaff (animal technician) and 
Dr. Sven Parsons (veterinarian) at the Animal Facility of the Faculty of Medicine and Health 
Sciences, Stellenbosch University, Tygerberg. The tissue analysis was performed in a blinded 
fashion. Here, each animal was assigned a unique experimental number that was randomized 
using Microsoft Excel (done by another researcher). The identity of the animals (genotype and 
treatment group) was hereby ‟hidden” and analysis performed on samples with only the 
experimental number known. 




Figure 2.3.1 A: (males). Illustration of the animal model and experimental design used to 
ascertain the role of TKTL1. 
A 




Figure 2.3.1 B: (females). Illustration of the animal model and experimental design used 
to ascertain the role of TKTL1. 




2.4 Sample preparation for oxidative stress and activity assay analyses: 
2.4.1 Blood samples 
On the day of termination, blood samples were collected in serum tubes via cardiac puncture. 
A 25 µl aliquot of whole blood was added to a microfuge tube followed by addition of 2.5 µl 1-
methyl-2-vinyl-pyridinium trifluoromethane sulfonate (M2VP, an anti-oxidant) (Sigma-Aldrich, 
St. Louis, MO). After 5 s of vortexing, the samples were stored at -80°C until GSSG assay 
was performed. The remaining blood was centrifuged at ~5000 x g for 10 min at 4°C and the 
serum subsequently divided into 25 µl aliquots that were stored at -80°C until further analyses. 
2.4.2 Tissue samples 
Upon tissue extraction, tissue sections were frozen at -80 °C. At the time of tissue preparation, 
two sections of tissue of each heart- and liver sample were weighed off. Roughly 30 mg was 
required for GSSG analysis and 100 mg for the rest of the oxidative stress analyses. Samples 
were then placed into ice-cold 1X phosphate buffered saline (PBS) containing 1X cOmpleteTM 
Protease Inhibitor Cocktail (Sigma-Aldrich, St. Louis, MO). The buffer of the GSSG samples 
contained 10 mM M2VP (Sigma-Aldrich, St. Louis, MO) in order to prevent further oxidation of 
GSH. Tissue was homogenized on ice using a Polytron PT 2100 homogenizer (Kinematica, 
Luzern, CH). The homogenates were subsequently centrifuged (Labnet, Edison, NJ) at 
~16000 x g for 10 min at 4°C and the supernatant was divided into several ~100 µl aliquots 
that were stored at -80°C until further analysis. 
2.5 Assessment of the pentose phosphate pathway (PPP)  
2.5.1 Glucose-6-phosphate dehydrogenase (G6PD) activity assay 
G6PD activity (the first and rate-limiting enzyme of the PPP) was monitored using a 
commercially obtained fluorimetric assay kit (Abcam, Cambridge, MA). This assay is based 
on the conversion of NADP+ by G6PD to yield NADPH. The latter triggers an NADPH sensor 
which fluoresces red and can be monitored at 590 nm. 




Heart and liver samples (refer Section 2.4.2) were subjected to protein concentration 
determination using the PierceTM BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, 
MA). Twenty-five µl of either blank, serial dilutions of G6PD, or the actual sample were added 
(in duplicate) to appropriate wells of a black-walled, clear, flat bottom 96 well plate. This was 
followed by the addition of 25 µl of assay mixture (enzyme probe and NADP+ in assay buffer) 
after which fluorescence intensity was kinetically monitored at 590 nm using a Fluoroskan 
AscentTM Microplate Fluorometer (Thermo Fisher Scientific, Waltham, MA) at 1 min intervals 
until the NADP+ conversion rate stabilized. 






Where: df = dilution factors required for the samples to fit the standard curve. 
2.5.2 NADP+/ NADPH assay 
A commercially available NADP+/ NADPH colorimetric assay (Abcam, Cambridge, MA) was 
employed to establish the respective concentrations of NADP+ and NADPH as well as 
estimate the NADP+: NADPH ratio in the heart and liver samples. At the time of the assay, an 
aliquot (refer to Section 2.2.2) of each sample was thawed, after which NADPH extraction 
buffer was added to dilute the samples. For heart samples, a 1:2 dilution sufficed, while liver 
samples required a 1:5 dilution. These samples contained the total NADPH (NADP+ and 
NADPH) and each was divided into two aliquots – one used to determine total NADPH and 
the other heated at 60°C for 30 min to decompose NADP+ in the samples.  
A serial dilution was used to generate a standard curve. Twenty-five µl of each blank, standard 
or sample was added to a clear 96-well plate in duplicate. The reaction mixture (50 µl), 
containing NADP+ cycling buffer and NADP+ cycling enzyme mix, was pipetted into each well. 
This was followed by an incubation period of 5 min at room temperature during which time the 




conversion of NADP+ to NADPH occurred. Hereafter, 5 µl of NADPH developer was added 
and optical density monitored at 450 nm for four 20 min intervals, using a MultiskanTM 
Spectrum Microplate Reader (Thermo Fisher Scientific, Waltham, MA), until the absorbance 
stabilized.  
The standard curve was plotted and the equation thereof determined. This allowed for the 
extrapolation of [NADPH] and total NADPH [NADPt] according to the following: 
[𝑁𝐴𝐷𝑃𝑡] =














With this assay some problems were encountered as the boiling step, which decomposed the 
NADP+ in the samples, led to the formation of fat drplets due to the high fat content of the liver 
samples. Unfortunetely, due to time constraints as well as the great expense of the kit used, 
we were unable to optimize this technique further. In future, I would recommend that samples 
be centrifuged at ~16000 x g for 30 min and the middle layer transferred to a new tube while 
taking special care not to disrupt the top lipid layer.  
2.5.3 Transketolase activity assay 
Transketolase activity, the main flux regulating enzyme of the PPP, was determined using an 
amended protocol from Diaz-Moralli and colleagues (2011). All (analytical grade) reagents 
used were purchased from Sigma Aldrich (St. Louis, MO). Twenty µl of each sample (heart 
and liver) was added in triplicate to 50 µl of assay buffer (50 mM Tris-HCl buffer pH 7.6, 5 mM 
MgCl2, 0.1 mM thiamine pyrophosphate [TPP], 0.2 mM β-NAD, 0.2 U/ ml α-glycerophosphate 
dehydrogenase-triosephosphate isomerase) to appropriate wells of a Greiner UV-Star®96-well 




plate (Sigma-Aldrich, St. Louis, MO). This was followed by the incubation of the foil-covered 
plate at 25°C for 10 min before the addition of the reaction solution (25 µl) that contained 15 
mM D-ribose-5-phosphate and 7.24 mM D-xylulose-5-phosphate. Subsequently, the 
absorbance was monitored at 340 nm for 10 min using an EZ Read 400 Microplate Reader 
(Biochrom, Cambridge, UK).  
Transketolase activity was calculated as follows: 
𝑈𝑛𝑖𝑡𝑠 𝑝𝑒𝑟 𝑚𝑙 𝑜𝑓 𝑒𝑛𝑧𝑦𝑚𝑒 =  






The values were presented as: 
𝑈𝑛𝑖𝑡𝑠 𝑝𝑒𝑟 𝑚𝑔 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 =  
𝑢𝑛𝑖𝑡𝑠 / 𝑚𝑙 𝑒𝑛𝑧𝑦𝑚𝑒
𝑚𝑔 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 / 𝑚𝑙 𝑒𝑛𝑧𝑦𝑚𝑒
 
(∆-change increment; A-absorbance; df-dilution factor; ml-millilitre; mg-milligram) 
Technical difficulties were experienced with the liver samples as negative values were 
obtained. The optimization of this in-house assay could not be performed as 1) time was a 
limiting factor as the reagents arrived late and not all at once, 2) some of the reagents were 
enough for only one set of activity assays, 3) the reagents were very expensive, and 4) there 
was too little sample left to prepare a complete set to try and optimize the assay.  
2.6 Determining the oxidative status of the serum and tissue 
Mr. Fanie Rautenbach from the Oxidative Stress Research Centre, Cape Peninsula University 
of Technology (Bellville, Western Cape) kindly provided the reagents, protocols, workspace 
and guidance to assess oxidative stress (all except NADPH oxidase assay) and anti-oxidant 
mechanisms. 




2.6.1 Indications of oxidative damage 
2.6.1.1 NADPH oxidase (NOX) activity 
We employed a modified protocol previously used in our laboratory derived from a NOX 
activity assay performed by Abid and colleagues (2007) (Joseph et al., 2014). The NOX 
complex generates electrons that can cause oxidative damage if there is higher activity. In this 
assay, the electrons generated by the NOX complex react with lucigenin, causing it to emit 
light that can be detected with a luminometer. 
For sample preparation refer to Section 2.4.2. Protein concentrations were determined using 
a Direct DetectTM instrument (Bio-Rad, Hercules, CA). Ten µl of the blank or sample (heart 
and liver) was added in triplicate. This was followed by the addition of 50 µl of assay buffer, 
containing 250 mM HEPES buffer (pH 7.4), 120 mM NaCl, 5.9 mM KCl, 1.2 mM MgSO4·7H2O, 
1.75 mM CaCl2·2H2O, 11 mM glucose, 0.5 mM EDTA, 100 μM NADH and 5 μM lucigenin. 
Luminescence was measured using a Glomax-96 luminometer (Promega, Madison, WI). NOX 
activity was expressed as relative light units (RLU)/ mg protein. 
2.6.1.2 Conjugated dienes (CDs) 
This assay estimates the levels of CDs in tissue and acts as a marker of early damage 
attributed to free radicals. For serum and tissue sample preparation, please refer to Sections 
2.4.1 and 2.4.2. Briefly, 90 µl of chloroform: methanol (2:1) solution was added to 20 µl (serum) 
or 45 µl (tissue) samples followed by a 10 s vortex step and 5 min centrifugation at 10000 x g 
at 4°C. Uncapped microfuge tubes were then left overnight at 4°C to allow for the evaporation 
of the solution. On the day of the assay, the residue was dissolved in 500 µl of cyclohexane 
followed by a 10 s vortex step. Next, 150 µl of each blank (cyclohexane) or sample was 
aliquoted in triplicate into the appropriate wells. The absorbance was read at 232 nm using a 
Fluoroskan AscentTM Microplate Fluorometer (Thermo Fisher Scientific, Waltham, MA). 












Where A= absorbance, ε = extinction coefficient (29500 L/mol/cm), df = dilution factor. 
2.6.1.3 Thiobutyric acid reactive substances (TBARS) 
Similar to the CDs assay above, the TBARS assay detects lipid peroxidation (specifically 
malondialdehyde [MDA]) that arises due to the actions of free radicals. However; this step 
occurs much further in the oxidative pathway and is therefore indicative of advanced damage. 
In this assay, an MDA:TBA complex is formed when heated to 90°C that can be monitored at 
535 nm. 
All chemicals (analytical grade) used were obtained from Sigma-Aldrich (St. Louis, MO). 
Briefly, 45 µl of 0.2 M orthophosphoric acid and 5.6 µl of cold 4 mM ethanol were added to 45 
µl of liver lysates. This was followed by a 10 s vortex step and the addition of 5.6 µl TBA 
reagent and again followed by a 10 s vortex step. Subsequently, samples were heated to 90°C 
for 45 min before being cooled for 2 min on ice. The samples were thereafter allowed to 
stabilize until it reached room temperature before 450 µl of n-butanol and 45 µl of saturated 
NaCl were added. After a 10 s vortex step, samples were centrifuged at 4°C for 2 min at ~ 
6000 x g. For heart samples (25 µl), the same ratios of the sample:reagents were used. Three 
hundred µl of blank (butanol) and each sample (top butanol layer) was then added in triplicate 
to appropriate wells of a 96-well clear plate after which the absorbance was monitored at 535 
nm using a MultiskanTM Spectrum Microplate Reader (Thermo Fisher Scientific, Waltham, 
MA). The same rations were used for heart samples (25 µl). 








Where ε = extinction coefficient (156000 l/mol/cm), df = dilution factor. 




2.6.2 Anti-oxidant mechanisms: 
2.6.2.1 Superoxide dismutase (SOD) activity assay 
This enzyme is responsible for the conversion of detrimental O2-· to a lesser reactive H2O2. In 
this assay, SOD is able to neutralize the auto-oxidation of ROS-inducer (6-hydroxydopamine 
(6-HD) that otherwise reacts with diethylenetriamine-pentaacetic acid (DETAPAC) to form a 
pink/orange colored complex that can be monitored with a microplate reader at 490 nm. 
Twelve µl of each sample (heart and liver) was added to wells (in triplicate) of a 96-well plate. 
Subsequently, 15 µl 6-HD (Sigma-Aldrich, St. Louis, MO) was added to each well. Following 
the addition of 170 µl DETAPAC (Sigma-Aldrich, St. Louis, MO), SOD activity was 
colorimetrically monitored at 490 nm in 30 s intervals for a total of 5 min using a MultiskanTM 
Spectrum Microplate Reader (Thermo Fisher Scientific, Waltham, MA). A commercially 
available PierceTM BCA Protein Assay Kit (Thermo Scientific, Waltham, MA) was utilized for 
the determination of the protein content of the samples, allowing for the expression of SOD 
activity as U/mg protein. 
SOD activity was calculated as follows: 
𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =




Although H2O2 is less reactive than superoxide radicals, it is still able to trigger damaging 
effects. Catalase is able to convert hydrogen peroxide to water and oxygen thereby 
neutralizing its detrimental effects. The catalase assay is based on the rate of H2O2 conversion 
from which we are able to infer catalase activity. 
Ten µl of each blank or sample (heart and liver) was added in triplicate to the appropriate wells 
followed by the addition of 170 µl catalase assay buffer (50 mM K3PO4, pH 7.0). Immediately 
after 75 µl H2O2 supplementation, the absorbance was read at 240 nm at 30 s intervals for a 




total of 5 min using a MultiskanTM Spectrum Microplate Reader (Thermo Fisher Scientific, 
Waltham, MA). 





× 𝑑𝑓  
Where ε = extinction coefficient (0.00394 mmol/L/cm), [protein] = protein concentration, df = 
applicable dilution factors.  
2.6.2.3 Ferric reducing anti-oxidant power (FRAP) 
FRAP refers to the reducing power of anti-oxidants that function via the single electron transfer 
mechanism. Vitamin C serves as the standard for this assay which is based on the ability of 
the sample to neutralize the reactivity of Fe3+ by reducing it to Fe2+ thereby allowing for the 
formation of a Fe2+: 2,4,6-Tris(2-pyridyl)-s-triazine (TPTZ) complex that is blue in color and 
can be detected at 593 nm.  
Five µl of each sample (blood, heart, and liver) was added to a clear 96-well plate in triplicate. 
This was followed by the addition of 300 µl of FRAP reagent (20 mM FeCl3, 10 mM TPTZ, 300 
mM acetate buffer (pH 3.6) in dH2O). Plates were covered and allowed to incubate at room 
temperature for 30 min before the absorbance was read at 593 nm using a MultiskanTM 
Spectrum Microplate Reader (Thermo Fisher Scientific, Waltham, MA). 
The concentration of FRAP was expressed as µM and calculated as follows: 
[𝐹𝑅𝐴𝑃] =





 × 𝑑𝑓 
Where df = dilution factor required to fit sample on the standard curve. 
2.6.2.4 Oxygen radical absorbance capacity (ORAC) 
This assay measures intracellular anti-oxidant capacity through the hydrogen atom transfer 
(HAT) mechanism that neutralizes radicals. The principle of this assay is based on a peroxyl 




radical 2,2’-Azobis(2-methylpropionamidine) dihydrochloride (AAPH) reacting with fluorescein 
(representing proteins and/or lipids) that has an Ex458 nm/Em530 nm. Anti-oxidants that function 
via the hydrogen atom transfer mechanism are able to partially inhibit this reaction, thereby, 
decreasing the emission of light from fluorescein at 530 nm. 
A standard curve was prepared using a 0.5 mM Trolox (synthetic vitamin E) stock solution. 
Twelve µl of each blank, standard, internal control* or sample (blood, heart or liver) was added 
(in triplicate) to a black 96-well plate. This was followed by the addition of 138 µl of fluorescein 
(Sigma-Aldrich, St. Louis, MO). Immediately prior to reading, 50 µl of AAPH (Sigma-Aldrich, 
St. Louis, MO) was added to each well. Light emission was monitored for 2 hours at 1 min 
intervals using a Fluoroskan AscentTM Microplate Fluorometer (Thermo Fisher Scientific, 
Waltham, MA). 
*Internal control used to standardize readings as assay was performed on multiple days. 
ORAC was expressed as Trolox equivalent (TE)/ dl and calculated using a regression equation 
between Trolox concentration (Y) and the net area under the fluorescence decay curve (AUC) 
(X) (µM): 
(Y =  a +  bX +  cX2) 
𝐴𝑈𝐶 =  (0.5 +  𝑓2/𝑓1 +  𝑓3/𝑓1 +  𝑓4𝑓1 +  … +  𝑓𝑖/𝑓1) 𝑥 𝐶𝑇 
Where f1 = initial fluorescence reading at cycle 1, fi = fluorescence reading at cycle i, and CT 
= cycle time in min. 
2.6.2.5 Glutathione levels 
The ratio of GSH: GSSG is commonly used as an indication of tissue oxidative status. In this 
assay, GSH in the sample converts 5,5′-Dithiobis(2-nitrobenzoic acid) (DTNB) to its reduced 
form (yellow color) and can be monitored at 412 nm. A standard curve is essential as it is used 
to extrapolate the concentrations of both GSH and GSSG in the samples. 




For the determination of GSH concentration in blood, heart and liver samples (refer Section 
2.2.1 and 2.2.2 for preparation), 175 µl of 5% metaphosphoric acid (MPA) was added to 25 µl 
of the sample followed by a 10 s vortex step. Samples were then centrifuged at 10000 x g for 
5 min at 4°C. Ten µl of the supernatant was thereafter added to 600 µl of Buffer A (500 mM 
NaPO4 and 1 mM EDTA). Fifty µl of blank, standard or sample was added in triplicate to a 96-
well clear plate. Subsequently, 50 µl of DNTB and 50 µl of glutathione reductase was added. 
Thereafter, NADPH (50 µl) was added followed by the monitoring of absorbance at 412 nm 
with a MultiskanTM Spectrum Microplate Reader (Thermo Fisher Scientific, Waltham, MA). 
The proteins of GSSG samples (as prepared in Sections 2.4.1 and 2.4.2) were precipitated by 
adding 72.5 µl of 5% MPA to 25 µl of the sample followed by a 10 s vortex step and 
centrifugation at 10000 x g for 5 min at 4 °C. Subsequently, 25 µl of supernatant was mixed 
with 350 µl of Buffer A and the same procedure was then followed (as described) to determine 
the GSH concentration. 
GSH and GSSG concentrations were expressed as µmol/g and calculated as follow:  
[𝐺𝑆𝐻] =  






[𝐺𝑆𝑆𝐺] =  





× 𝑑𝑓 × 2∗ 
Where GSH = reduced glutathione, GSSG = oxidized glutathione, df = dilution factors 
*Structurally GSH = 2 x GSSG with a disulfide bond connecting the two molecules. 
2.7 Histological analysis  
2.7.1 Sample preparation for histological analysis 
Upon harvesting, heart samples (n=2) and liver samples (n=4) of each group samples were 
stored in formaldehyde solution (Sigma-Aldrich, St. Louis, MO) until further processing. An 
automated tissue processor was used to fix (paraformaldehyde), dehydrate (increasing 
concentrations of ethanol), clear (xylene) and embed (paraffin) tissue samples. Prior to 




sectioning, samples were re-embedded with paraffin wax. Serial sections of tissue samples 
were obtained using a Leica RM2125 RT (Leica, Wetzlar, DE) microtome. These were then 
rehydrated and fixed on a microscope slide until staining ensued.  
2.7.2 Hematoxylin and eosin (H&E) staining 
Sections were stained using a Leica ST4020 (Leica, Wetzlar, DE) automated stainer in the 
following sequence: xylene, xylene, 100% ethanol, 95% ethanol, 70% ethanol, H2O, 
Hematoxylin, warm H2O, Scott’s water, H2O, Eosin, H2O, 95% ethanol and 100% ethanol, with 
sections immersed in each solution for 2 min. After air-drying, sections were sealed with 
Mounting Medium (Sigma-Aldrich, St. Louis, MO) and coverslips. Dr. Carol Chase, a retired 
histologist kindly assisted in the initial analysis of ultrastructure (H&E) and possible changes 
thereof. Images were taken using a Nikon DS-Fi2 camera fitted to a Nikon eclipse e400 
microscope (Minato, TYO, Japan). Five random regions of interest were taken at 20X 
magnification as well as a whole section image at 4X magnification. 
2.7.3 Sirius red stain: identifying possible fibrosis 
Deparaffinized sections were stained with Picro-Sirius red for one hour prior to two 2 min 
immersions in (0.5% v/v) acetic acid solution. Subsequently, sections were subjected to two 
changes of 100% ethanol followed by a clearing step with xylene. Slides were allowed to air-
dry after which they were mounted with Mounting medium (Sigma-Aldrich, St. Louis, MO) and 
a coverslip. Microscopic analysis was done using a Nikon Eclipse E400 and images (five 
random fields of view [20X] and whole section image [4X]) were obtained with a Nikon DS-Fi2 
camera (Minato, TYO, Japan). Collagen content and/or fibrosis was quantified using ImageJ 
combined with a color thresholding algorithm developed by G. Landini (Hadi et al., 2011). 
% 𝑓𝑖𝑏𝑟𝑜𝑠𝑖𝑠 =
𝑎𝑟𝑒𝑎 𝑜𝑓 𝑓𝑖𝑏𝑟𝑜𝑠𝑖𝑠
𝑡𝑜𝑡𝑎𝑙 𝑎𝑟𝑒𝑎 + 𝑎𝑟𝑒𝑎 𝑜𝑓 𝑓𝑖𝑏𝑟𝑜𝑠𝑖𝑠
 




2.8 Western Blot analysis: apoptotic cell death 
Roughly 100 mg of each heart and liver sample was weighed off and submerged in 1 ml of ice 
cold radioimmunoprecipitation assay buffer (RIPA) containing 1X cOmpleteTM Protease 
Inhibitor Cocktail (Sigma-Aldrich, St. Louis, MO), 1 mM sodium orthovanadate, 1 mM sodium 
fluoride , and 1 mM phenylmethylsulfonyl fluoride (PMSF). Thereafter, samples were cut into 
small pieces using sharp scissors, taking care to sterilize the instruments between samples 
as to prevent contamination of the samples. Samples were then homogenized on ice using a 
Polytron PT 2100 homogenizer (Kinematica, Luzern, CH). Subsequently, homogenates were 
centrifuged (Labnet, Edison, NJ) at ~16000 x g for 10 min at 4°C and the supernatants were 
stored at -80°C until further preparation.  
In the second preparation phase, samples were thawed on ice.  Five microliter of each sample 
was added to a clean tube which served as the loading control. Protein concentration was 
determined using a Direct DetectTM instrument (Bio-Rad, Hercules, CA) and was used to 
determine the amount of each sample, 2X Laemmli buffer (containing 2-β-mercaptoethanol) 
and RIPA buffer to be added to each sample tube to be loaded onto the gel. 
Heart and liver samples were subjected to Western Blotting analysis routinely performed in 
our laboratory using 15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis hand-
cast gels (Joseph et al., 2014; Joseph and Essop, 2014; Mapanga et al., 2014). These gels 
were transferred onto polyvinyldene fluoride membranes (Bio-Rad, Hercules, CA) using a 
Trans-Blot® TurboTM Transfer system (Bio-Rad, Hercules, CA) that were subsequently blocked 
with 5% fat-free milk in 1% Tris-buffered saline-0.1% Tween (TBS-T). Membranes were 
subsequently incubated with a 1:1000 Caspase-3 (Cas-3) (8G10) Rabbit mAB (Cell Signaling 
Technology, Danvers, MA) antibody made up in the blocking solution overnight at 4°C followed 
by a 1 hour incubation with 1:10000 anti-rabbit IgG HRP-linked antibody (Cell Signaling 
Technology, Danvers, MA) in 5% fat free milk - 1% TBS-T at room temperature. Total protein 
was visualized with UV light using a ChemiDocTM MP System (Bio-Rad, Hercules, CA), while 
the protein of interest was detected using enhanced chemiluminescence (Bio-Rad, Hercules, 




CA). Western blots were analysed using the “Total lane protein” method of Image LabTM 
Software to determine the relative concentration of the protein of interest as a percentage of 
the loading control.  
Troubleshooting of Western blots: 
The first set of Western blots contained streaks believed to be due to the high fat content. The 
quality of the blots were improved by using the same preparation used for the oxidative status 
tests and activity assays (refer Section 2.4.2) as well as increasing the centrifuge time and 
speed. Samples were centrifuged at ~16000 x g for 30 min at 4°C and the supernatant 
aliquoted into a new tube. These samples were stored at -80°C until further preparation as 
described above. 
 2.9 Statistical Analysis 
Statistical analyses were performed using STATISTICA 13.2.92.1. Normality was tested by 
means of a Normal Probability Plot which takes into account Kolmogorov–Smirnov, Lilliefors, 
and Shapiro-Wilk values. Subsequently, Levene’s test for homogeneity of variances was 
calculated. Data that were not normally distributed, was transformed using the BoxCox 
transformation. Statistical significance between groups was determined with either a Two-way 
analysis of variance (ANOVA) or Three-way ANOVA, depending on the independent 
variables. This was followed by a Fisher’s least significant difference post-hoc test for normally 
distributed data or by a Games-Howell post hoc test for transformed data. Spearman’s 
correlation coefficient was used to determine whether or not correlations existed between 
experimental values and blood glucose levels. P-values were considered statistically 
significant if p<0.05. GraphPad PRISM version 5.0 was used to present statistical data. 
  




Chapter 3: Results 
For this project we aimed to 1) establish an STZ-mouse model to induce hyperglycemia in wild 
type (WT) and TKTL1-knock-out (KO) mice, 2) assess the oxidative status of highly metabolic 
tissues (liver, heart) as well as in circulation, 3) evaluate downstream effects of hyperglycemia 
in the aforementioned tissues, 4) Evaluate the putative protective action of TKTL1 against 
hyperglycemia-mediated oxidative stress and downstream effects thereof, and 5) assess the 
contribution of TKTL1 to total transketolase activity. We employed a TKTL1-KO mouse model 
as a targeted approach to evaluating TKTL1 function. Briefly, animals received injections of 
either citrate buffer or low doses (40 mg/kg) of STZ on five consecutive days (Furman, 2015). 
Treatment with STZ destroys insulin-producing pancreatic β-cells and therefore leads to 
hyperglycemia, a pathophysiologic state known to culminate in oxidative stress and damaging 
outcomes (refer Chapter 1). 
3.1 Genotyping of WT and TKTL1-KO mice to be used in this study 
We initially identified WT and TKTL1-KO mice by genotyping PCR analysis of genomic DNA 
extracted from tail tissue, with the aim to breed greater numbers for subsequent experiments 
(Bentz et al. 2011). The deletion of exon 4 to exon 7 results in a shortened gene fragment of 
~338 bp. Our genotyping PCR results (analyzed by agarose gel electrophoresis) shows a 
distinct band at ~338 bp in TKTL1-KO mouse tail tissues, whereas the WT animals displayed 
no bands (refer Figure 3.1.1). Mice were subsequently divided into WT or TKTL1-KO groups 
according to the PCR results and then subjected to STZ treatment. 
 




Figure 3.1.1 Genotyping PCR analysis of WT and TKTL1-KO mice. WT: wild type, KO: 
knock-out, NC: negative control. 
3.2 Differential development of STZ-induced hyperglycemia  
We employed a GlucoPlusTM glucometer to measure non-fasting blood glucose levels from 
tail-veins weekly until the following criteria for hyperglycemia were met: 1) statistically 
significant non-fasting blood glucose levels in STZ injected groups vs. controls, 2) mean, non-
fasting blood glucose levels ≥200 mg/dl (11.1 mmol/L), 3) ≥90% hyperglycemia incidence (i.e. 
the percentage of animals in STZ treated groups displaying non-fasting blood glucose levels 
≥11.1 mmol/L on two consecutive reading days) (Wu and Huan, 2008; Furman, 2015; Lazar 
et al., 1968). Female mice in both WT and TKTL1-KO groups showed resistance to STZ-
induced hyperglycemia, as none of the groups displayed non-fasting blood glucose ≥11.1 
mmol/L (refer Figure 3.2.1 A). Our results indicate that the male TKTL1-KO STZ group 
displayed higher blood glucose levels compared to both the WT control group (p<0.001) and 
the TKTL1-KO control group (p<0.001) at termination (i.e. 7 weeks after completion of the STZ 
injection protocol) (refer Figure 3.2.1 B). The WT group treated with STZ did not exhibit a 
significantly higher blood glucose compared to the WT control group. As only 40% of the WT 
STZ-treated males reached hyperglycemia, we clustered these mice as responders (blood 
glucose ≥ 11.1 mmol/L, refer Figure 3.2.1 C) and non-responders (blood glucose < 11.1 
mmol/L, refer Figure 3.2.1 D). Data was then re-analyzed separately in order to determine 
whether the non-responder group affected the results. However, blood glucose levels for this 
group was not significantly higher (p=0.08) than the WT control group (criterion 1). The mean 
non-fasting blood glucose was, however, concealed by the non-responding mice. Here non-
responders showed a mean blood glucose level of 9.08 ± 0.34 mmol/L compared to 14.67 ± 
1.71 mmol/L for the responders. 




Figure 3.2.1 Non-fasting blood glucose levels of female (A) and male mice: B (combined 
data), C (responding, WT-STZ), D (non-responding, WT-STZ) mice at termination (7 
weeks post-STZ protocol). Data presented as mean ± SEM, n=5 (females), n=10 (males), 
WT STZ-responders n=4, WT STZ non-responders n=6, ***p<0.001 vs. WT control, 
###p<0.001 vs. TKTL1-KO control, $$$p<0.001 vs. WT STZ. The dotted line indicates the 
11.1 mmol/L cut-off value (criterion 2). 
 
Hyperglycemia incidence (percentage of mice displaying non-fasting blood glucose ≥11.1 
mmol/L) was 30% and 45% in WT and TKTL1-KO STZ-injected male groups, respectively, 
one week after the STZ injection protocol ended (refer Figure 3.2.2). This increased to 40% 
and 54% in the respective groups by weeks 2 to 3. The TKTL1-KO animals displayed a sharp 
increase in hyperglycemia incidence (to 81.8%) from week 4 and reached 90% (criterion 3) 
after 7 weeks, while that of the WT animals remained at a plateau (40%) throughout. Although 
both STZ-treated groups displayed a mean non-fasting blood glucose concentration of ≥11.1 
mmol/L (criterion 2) after 7 weeks, this was achieved earlier and to a greater extent in the 
TKTL1-KO group. These levels ranged from 9.64 ± 0.69 mmol/L (week 1) to 11.34 ± 1.12 
mmol/L (week 7) in WT mice, and from 10.76 ± 0.71 mmol/L (week 1) to 14.5 ± 0.89 mmol/L 
(week 7) in the TKTL1-KO group (refer Figure 3.2.3). 





Figure 3.2.2 Hyperglycemia incidence in male mice. Blood glucose was measured weekly 
and values are expressed as the percentage animals displaying glycemic values ≥11.1 mM 
per group (n=10). The dotted line indicates the 90% hyperglycemia incidence cut-off (criterion 
3). 
 
Figure 3.2.3 Development of hyperglycemia – temporal analysis. Blood glucose levels 
were weekly assessed and values expressed as mean ± SEM, n=10. *p<0.05, ***p<0.001 WT 
control vs. WT STZ; ###p<0.001 TKTL1-KO control vs. TKTL1-KO STZ. The dotted line 
indicates the 11.1 mmol/L cut-off value (criterion 2). 
  

















































3.3 Body weights of male and female mice largely unaffected by STZ treatment 
Body weights were measured weekly as a general indication of animal welfare (Foltz, 1999; 
Ullman-Culleré and Foltz, 1999). Within the male groups, TKTL1-KO STZ-injected mice 
displayed moderately lowered body weights compared to the WT control group (*p=0.04) 
(refer Figure 3.3.1 A). No other changes were noted within the groups (refer Figure 3.3.1). 
 
Figure 3.3.1 Body weights of male (A) and female (B) mice were largely unchanged. Data 
presented as mean ± SEM. *p<0.05 vs. WT control, n=10 (males) and n=5 (females). 
 
3.4 Assessment of organ weights in relation to body weight 
Following the assessment of blood glucose and body weight, we next evaluated specific organ 
weights (heart, liver, pancreas, kidney, gastrocnemius muscle and mammary fat pads 
(females). Organ weights are expressed as a percentage of body weight (refer Table 3.4). 
In the male mice, relative organ weight alterations were restricted to the TKTL1-KO mice, with 
the STZ-treated group displaying the most changes. The male TKTL1-KO STZ-treated group 
displayed larger relative liver weights compared to controls (p<0.001). An increase was also 
noted in the relative kidney weights of both TKTL1-KO groups. Gastrocnemii of the TKTL1-
KO STZ-treated group was lower than that of the WT control group (p<0.01). The inguinal 
mammary fat pads of the female TKTL1-KO STZ-treated group displayed lowered relative 
weight compared to the TKTL1-KO control group. 




Table 3.4 Organ weights as a percentage of body weight. 
Gender Genotype Treatment  Heart  Liver  Pancreas  Kidneys  Gastrocnemii  Inguinal fat pad  
Male WT Control 0.482 ± 0.01 4.885 ±0.07 0.508 ± 0.04 1.216 ± 0.01 1.145 ± 0.01 n/a 
STZ 0.443 ± 0.03 5.168 ±0.27 0.600 ± 0.03 1.189 ± 0.02 1.107 ± 0.02 n/a 
TKTL1-KO Control 0.523 ± 0.02 4.734 ±0.15 0.606 ± 0.05 1.423 ± 0.05*** 1.043 ± 0.05 n/a 
STZ 0.490 ± 0.03 5.8184 ±0.17***, ### 0.590 ± 0.03 1.327 ± 0.03*, #,$$ 1.043 ± 0.02** n/a 
Female WT Control 0.522 ± 0.03  5.026 ± 0.22 0.594 ±0.10 1.197 ± 0.08 0.953 ± 0.03 0.278 ± 0.06 
STZ 0.456 ± 0.04 4.909 ± 0.36 0.625 ±0.05 1.222 ± 0.04 0.965 ± 0.02 0.335 ± 0.05 
TKTL1-KO Control 0.519 ± 0.04 4.892 ± 0.18 0.694 ±0.04 1.257 ± 0.06 0.884 ± 0.07 0.538 ± 0.07* 
STZ 0.542 ± 0.03 4.761 ± 0.10 0.538 ±0.08 1.281 ± 0.04 0.960 ± 0.04 0.266 ± 0.09## 
Organ weights expressed as percentage of body weight ± SEM. *p<0.05 vs. WT control, #p<0.05 vs. TKTL1-KO control, **p<0.01 vs. WT control, 
$$p<0.01 vs. WT STZ, ***p<0.001 vs. WT control, ###p<0.001 vs. TKTL1-KO control, n=10 (males), n= 5 (females). 
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3.5 Analysis of the PPP 
Next we aimed to analyze the PPP in depth and employed a commercially available kit to 
assess G6PD activity, the initial rate-limiting enzyme of the PPP’s oxidative branch (Pandolfi 
et al., 1995). We subsequently tested the concentrations of NADPH and NADP+, a by-product 
of the G6PD reaction, with a commercially available kit. Due to some technical difficulties, only 
the NADPHt (NADPH + NADP+) could be quantified. Next, we employed a published method 
for the quantification of transketolase activity (Diaz-Moralli et al., 2011). Here total 
transketolase activity was measured as there is no assay specifically for TKTL1 activity per 
se, the flux controlling enzyme of the non-oxidative branch of the PPP and the main focus of 
this project (Berthon et al., 1992; Schenk et al., 1998).  
3.5.1 G6PD activity 
G6PD activity was measured in both heart and liver samples (refer Figures 3.5.1.1 and 
3.5.1.3). No significant alterations in G6PD activity were observed in the heart of any of the 
experimental groups. Animals that were sensitive to the hyperglycemia-inducing effects of 
STZ (responders) had higher mean G6PD activity when analyzed separately, however, this 
was still not significantly different when compared to controls (Figure 3.5.1.1 B). We further 
aimed to investigate whether a correlation existed between G6PD activity and blood glucose 
levels. Here we found no significant correlation exists for heart samples (Figure 3.5.1.2). The 
liver G6PD activity was also not significantly changed in any of the groups (Figure 3.5.1.3 A), 
while separate analysis of WT responders and non-responders yielded similar results (Figure 
3.5.1.3 B and C). Interestingly, there was a significant, moderate negative correlation between 
liver G6PD activity and blood glucose levels (r=-0.37, p=0.03; Figure 3.5.1.4). 
  





Figure 3.5.1.1 G6PD activity in the heart: A (combined data), B (WT STZ responders), C 
(WT STZ non-responders). Data presented as mean ± SEM, n=8. WT STZ responders n=3 
(B), WT STZ non-responders n=5, (C). 
 
 
Figure 3.5.1.2 No significant correlation between G6PD activity in the heart and blood 
glucose concentrations. Spearman’s correlation coefficient r = 0.03, p=0.87. 





Figure 3.5.1.3 G6PD activity in the liver: A (combined data), B (WT STZ responders), C 
(WT STZ non-responders). Data presented as mean ± SEM, n=8. WT STZ responders n=3 
(B), WT STZ non-responders n=5, (C). 
 
 
Figure 3.5.1.4 Significant, moderate negative correlation of G6PD activity in the liver 
with increasing blood glucose concentrations. Spearman’s correlation coefficient r = -0.37, 
p=0.03. 




3.5.2 NADPt concentration 
As mentioned in the Methods, we encountered technical difficulties with this assay due to fat 
droplet formation (in the boiling step) which interfered with the absorbance readings. Therefore 
only the NADPt reading was obtainable (refer Figure 3.5.2). No significant differences were 
found for NADPt levels for the heart groups (Figure 3.5.2.1). Separation of WT-STZ 
responders and non-responders had no effect. NADPt levels also did not show any correlation 
with blood glucose levels (Figure 3.5.2.2). Liver NADPt levels were also not significantly 
different between groups (Figure 3.5.2.3). One of the TKTL1-KO control data points were 
highly elevated compared to the other values within this group. No correlation exists between 
NADPt levels and blood glucose concentration (Figure 3.5.2.4). 
 
Figure 3.5.2.1 NADPt(NADPH+NADP+) in the heart: A (combined data), B (WT STZ responders), 
C (WT STZ non-responders). Data presented as mean ± SEM, n=8. WT STZ responders 
n=3 (B), WT STZ non-responders n=5, (C). 





Figure 3.5.2.2 Lack of correlation between NADPt (NADPH+NADP+) levels and blood glucose 
concentrations in the heart. Spearman’s correlation coefficient r = 0.11, p=0.56. 
 
 
Figure 3.5.2.3 NADPt (NADPH+NADP+) in the liver: A (all data), B (responders), C (non-
responders). Data presented as mean ± SEM, n=8. WT STZ responders n=3 (B), WT STZ 
non-responders n=5, (C). 

































 Spearman r = 0.11 p=0.56





Figure 3.5.2.4 No correlation between NADPt (NADPH+NADP+) levels in the liver and blood 
glucose concentrations. Spearman’s correlation coefficient r = -0.13, p=0.44. 
 
3.5.3 Transketolase activity 
Total transketolase activity was measured in heart and liver samples using an in-house assay 
modified from Diaz-Moralli and colleagues (2011). In the heart, both TKTL1-KO groups 
displayed ~50% diminished transketolase activity compared to the WT control (p<0.001) 
(Figure 3.5.3.1). The heart transketolase activity in the WT STZ group was ~68% of that in the 
WT control group (p<0.05). Of note, responders and non-responders each had similar effects 
on transketolase activity (Figure 3.5.3.1 B and C). Liver transketolase activity presented 
negative values, indicating technical difficulties. No significant differences in liver 
transketolase activity were observed between any of the groups. Furthermore, there was no 
correlation between heart transketolase activity and blood glucose levels (Figure 3.5.3.2). 































 Spearman r = -0.13 p=0.44





Figure 3.5.3.1 Total transketolase activity in the heart: A (combined data), B (WT STZ 
responders), C (WT STZ non-responders). Data presented as mean ± SEM, n=8. WT STZ 
responders n=3 (B), WT STZ non-responders n=5, (C). *p<0.05 vs. WT control, **p<0.01 vs. 
WT control, ***p<0.001 vs. WT control. 
 
 
Figure 3.5.3.2 Lack of correlation between total transketolase activity in the heart and 
blood glucose concentrations. Spearman’s correlation coefficient r = -0.07, p=0.71. 






























 Spearman r = -0.07 p=0.71




Figure 3.5.3.3 Total transketolase activity in the liver: A (combined data), B (WT STZ 
responders), C (WT STZ non-responders). Data presented as mean ± SEM, n=8. WT STZ 
responders n=3 (B), WT STZ non-responders n=5, (C). 
 
 
Figure 3.5.3.4 Non-significant, moderately negative correlation between total 
transketolase activity in the liver and blood glucose concentrations. Spearman’s 
correlation coefficient r = -0.30, p=0.08. 
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3.6 Evaluation of oxidative status 
One of the main aims of this study was to evaluate the putative role of TKTL1 in the oxidative 
status of STZ-induced hyperglycemic mice. As described in Section 2.3, mice were injected 
with either STZ (40 mg/kg, i.p.) or citrate buffer for five consecutive days after which blood 
glucose levels were periodically monitored until hyperglycemia was established. Tissues were 
then collected for analyses. Here we sought to evaluate the oxidative status of blood, heart 
and liver samples by assessing indicators of oxidative stress and damage as well as an 
evaluation of anti-oxidant mechanisms. 
3.6.1 NOX activity 
We started by assessing NOX activity as it is one of the major ROS producing systems in 
many cell types. Here we employed an in-house luminescence assay protocol adapted from 
previous work (Abid et al. 2007). No significant differences in NOX activity were noted between 
any of the groups in either the heart (Figure 3.6.1.1) or the liver (Figure 3.6.1.3). However, this 
could be due to the immense variability within the groups, especially in the heart samples. 
Notably, NOX activity of the liver greatly exceeds (~10X) that of the heart. NOX activity was 
also not correlated with blood glucose (Figures 3.6.1.2 and 3.6.1.4). 
  





Figure 3.6.1.1 NOX activity in the heart: A (all data), B (responders), C (non-responders). 




Figure 3.6.1.2 No correlation between NADPH oxidase activity in the heart and blood 
glucose concentrations. Spearman’s correlation coefficient r = -0.11, p=0.55. 













































 Spearman r = -0.11 p=0.55





Figure 3.6.1.3 NOX activity in the liver: A (combined data), B (WT STZ responders), C 
(WT STZ non-responders). Data presented as mean ± SEM, n=8. WT STZ responders n=3 
(B), WT STZ non-responders n=5, (C). 
 
 
Figure 3.6.1.4 No correlation between NADPH oxidase activity in the liver and blood 
glucose concentrations. Spearman’s correlation coefficient r = -0.11, p=0.54. 
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3.6.2 Quantification of CDs 
We next analyzed markers of oxidative damage in circulation, as well as in heart and liver 
tissues. CD concentration (an early indicator of lipid peroxidation) was not significantly altered 
in the blood (Figure 3.6.2.1), heart (Figure 3.6.2.3), or liver (Figure 3.6.2.5) of any of the 
groups. This was despite a ~21% and ~37% decrease in blood and liver, respectively, of WT 
STZ-treated animals. Separation of responders and non-responders did not alter this result. 
Furthermore, there were no correlations between CDs and blood glucose levels in any of the 
tested samples (Figure 3.6.2.2, Figure 3.6.2.4, and Figure 3.6.2.6). However, when analyzing 
WT and TKTL1-KO samples separately, we observed a strong negative and significant 
correlation between CDs in the liver and blood glucose levels of WT mice (Spearman 
correlation coefficient r=-0.47, p= 0.05, data not shown, refer Appendix B for statistical table). 
This was not observed in the TKTL1-KO animals.  
 
Figure 3.6.2.1 CDs in circulation: A (combined data), B (WT STZ responders), C (WT STZ 
non-responders). Data presented as mean ± SEM, n=8. WT STZ responders n=3 (B), WT 
STZ non-responders n=5, (C). 





Figure 3.6.2.2 No correlation between CDs in the blood and blood glucose 
concentrations. Spearman’s correlation coefficient r = -0.17, p=0.31. 
 
 
Figure 3.6.2.3 CDs in the heart: A (combined data), B (WT STZ responders), C (WT STZ 
non-responders). Data presented as mean ± SEM, n=8. WT STZ responders n=3 (B), WT 
STZ non-responders n=5, (C). 






























 Spearman r = -0.17 p=0.31





Figure 3.6.2.4 No correlation between CDs in heart tissue and blood glucose 
concentrations. Spearman’s correlation coefficient r = 0.05, p=0.78. 
 
 
Figure 3.6.2.5 CDs in the liver: A (combined data), B (WT STZ responders), C (WT STZ 
non-responders). Data presented as mean ± SEM, n=8. WT STZ responders n=3 (B), WT 
STZ non-responders n=5, (C). 































 Spearman r = 0.05 p=0.78





Figure 3.6.2.6 No correlation between CDs in liver tissue and blood glucose 
concentrations. Spearman’s correlation coefficient r = -0.09, p=0.59. 
 
3.6.3 Quantification of TBARS in blood, heart, and liver samples 
We next assessed TBARS, a marker of lipid peroxidation. No significant differences were 
detected in TBARS concentration in circulation (Figure 3.6.3.1), heart (Figure 3.6.3.3), or liver 
(Figure 3.6.3.5). 
 
Figure 3.6.3.1 TBARS in circulation: A (combined data), B (WT STZ responders), C (WT 
STZ non-responders). Data presented as mean ± SEM, n=8. WT STZ responders n=3 (B), 
WT STZ non-responders n=5, (C). 
































 Spearman r = -0.09 p=0.59





Figure 3.6.3.2 No correlation between TBARS in blood and blood glucose 
concentrations. Spearman’s correlation coefficient r = -0.17, p=0.33. 
 
 
Figure 3.6.3.3 TBARS in the heart: A (combined data), B (WT STZ responders), C (WT 
STZ non-responders). Data presented as mean ± SEM, n=8. WT STZ responders n=3 (B), 
WT STZ non-responders n=5, (C). 


































 Spearman r = -0.17 p=0.33





Figure 3.6.3.4 No correlation between TBARS in heart tissue and blood glucose 
concentrations. Spearman’s correlation coefficient r = 0.08, p=0.67. 
 
 
Figure 3.6.3.5 TBARS in the liver: A (combined data), B (WT STZ responders), C (WT STZ 
non-responders). Data presented as mean ± SEM, n=8. WT STZ responders n=3 (B), WT 
STZ non-responders n=5, (C). 
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Figure 3.6.3.6 No correlation between TBARS in liver tissue and blood glucose 
concentrations. Spearman’s correlation coefficient r = 0.05, p=0.76. 
 
3.6.4 SOD activity in heart and liver samples 
We next proceeded to assess the status of anti-oxidant capacity in our model. SOD activity in 
both the heart (Figure 3.6.4.1) and liver (Figure 3.6.4.3) were unchanged. There were also no 
correlation between SOD activity and blood glucose levels for either of the tissues (Figures 
3.6.4.2 and 3.6.4.4). 




































 Spearman r = 0.05 p=0.76





Figure 3.6.4.1 SOD activity in the heart: A (combined data), B (WT STZ responders), C 
(WT STZ non-responders). Data presented as mean ± SEM, n=8. WT STZ responders n=3 
(B), WT STZ non-responders n=5, (C). 
 
 
Figure 3.6.4.2 No correlation between SOD activity in the heart tissue and blood glucose 
concentrations. Spearman’s correlation coefficient r = -0.09, p=0.63. 

































 Spearman r = -0.09 p=0.63





Figure 3.6.4.3 SOD activity in the liver: A (combined data), B (WT STZ responders), C 
(WT STZ non-responders). Data presented as mean ± SEM, n=8. WT STZ responders n=3 
(B), WT STZ non-responders n=5, (C). 
 
 
Figure 3.6.4.4 No correlation of SOD activity in the liver tissue with blood glucose 
concentrations. Spearman’s correlation coefficient r = -0.08, p=0.65. 

































 Spearman r = -0.08 p=0.65




3.6.5 Catalase activity in heart and liver samples 
No significant differences in catalase activity were detected in the heart in any of the groups 
(Figure 3.6.5.1), while this also did not correlate with blood glucose levels (Figure 3.6.5.2). 
Streptozotocin-treated TKTL1-KO mice displayed increased catalase activity in the liver 
(p<0.05 vs. WT control, p<0.05 vs. TKTL1-KO control, Figure 3.6.5.3). Furthermore, liver 
catalase activity showed a significant, moderate positive correlation with blood glucose when 
all study animals (WT and TKTL1-KO) were considered (r=0.39, p=0.02, Figure 3.6.5.4). This 
relationship was lost in the WT group alone. However, TKTL1-KO livers showed a strong 
positive correlation (r=0.53, p=0.02, data not shown, refer Appendix B for statistical table). 
 
Figure 3.6.5.1 Catalase activity of the heart: A (combined data), B (WT STZ responders), 
C (WT STZ non-responders). Data presented as mean ± SEM, n=8. WT STZ responders 
n=3 (B), WT STZ non-responders n=5, (C). 





Figure 3.6.5.2 No correlation of catalase activity in the heart tissue with blood glucose 
concentrations. Spearman’s correlation coefficient r = -0.02, p=0.89. 
 
 
Figure 3.6.5.3 Catalase activity of the liver: A (combined data), B (WT STZ responders), 
C (WT STZ non-responders). Data presented as mean ± SEM, n=8. WT STZ responders 
n=3 (B), WT STZ non-responders n=5, (C).*p<0.05 vs. WT control, #p<0.05 vs. TKTL1-KO 
control. 













































 Spearman r = -0.02 p=0.89





Figure 3.6.5.4 Positive correlation between hepatic catalase activity and blood glucose 
concentrations. Spearman’s correlation coefficient r = 0.39, p=0.02. 
 
3.6.6 FRAP measurements in blood, heart and liver samples 
We measured FRAP as an indicator of single electron transfer anti-oxidants. No significant 
differences were noted in the blood (Figure 3.6.6.1) and heart (Figure 3.6.6.2). FRAP 
concentrations were, however, significantly decreased in STZ-treated TKTL1-KO liver tissue 
(p<0.05 vs. TKTL1-KO control, Figure 3.6.6.3). Furthermore, liver FRAP showed a strong 
negative correlation with blood glucose levels when assessing all data points (r=0.45, p<0.01, 
Figure 3.6.6.6). WT animals did not display this correlation. However, TKTL1-KO animals 
showed a strong correlation (r=-0.54, p=0.02, data not shown, refer Appendix B for statistical 
table). 











































 Spearman r = 0.39 p=0.02





Figure 3.6.6.1 FRAP in circulation: A (combined data), B (WT STZ responders), C (WT 
STZ non-responders). Data presented as mean ± SEM, n=10. WT STZ responders n=4 (B), 
WT STZ non-responders n=6, (C). 
 
 
Figure 3.6.6.2 Non-significant negative correlation between systemic FRAP levels and 
blood glucose concentrations. Spearman’s correlation coefficient r = -0.26, p=0.12. 





Figure 3.6.6.3 FRAP in the heart: A (combined data), B (WT STZ responders), C (WT STZ 
non-responders). Data presented as mean ± SEM, n=8. WT STZ responders n=3 (B), WT 
STZ non-responders n=5, (C). 
 
 
Figure 3.6.6.4 No correlation between FRAP in the heart tissue and blood glucose 
concentrations. Spearman’s correlation coefficient r = 0.02, p=0.92. 



































 Spearman r = 0.02 p=0.92





Figure 3.6.6.5 FRAP in the liver: A (combined data), B (WT STZ responders), C (WT STZ 
non-responders). Data presented as mean ± SEM, n=8. WT STZ responders n=3 (B), WT 
STZ non-responders n=5, (C). #p<0.05 vs. TKTL1-KO control. 
 
 
Figure 3.6.6.6 Significant negative correlation between hepatic FRAP levels and blood 
glucose concentrations. Spearman’s correlation coefficient r = -0.45, p=0.01. 



































 Spearman r = -0.45 p=0.01




3.6.7 ORAC quantification in heart and liver samples 
ORAC is an indicator of total anti-oxidant capacity and is measured in Trolox ( anti-oxidant) 
equivalents. However, it was not significantly altered in circulation (Figure 3.6.7.1) or in the 
heart (Figure 3.6.7.2). ORAC of the TKTL1-KO control group was significantly higher in the 
liver versus the WT control (p<0.01) (Figure 3.6.7.3). 
Figure 3.6.7.1 ORAC in circulation: A (combined data), B (WT STZ responders), C (WT 
STZ non-responders). Data presented as mean ± SEM, n=10. WT STZ responders n=4 (B), 
WT STZ non-responders n=6, (C). 
 





Figure 3.6.7.2 No correlation between systemic ORAC and blood glucose 
concentrations. Spearman’s correlation coefficient r = 0.04, p=0.82. 
 
 
Figure 3.6.7.3 ORAC in the heart: A (combined data), B (WT STZ responders), C (WT STZ 
non-responders). Data presented as mean ± SEM, n=8. WT STZ responders n=3 (B), WT 
STZ non-responders n=5, (C). 

























 Spearman r = 0.04 p=0.82





Figure 3.6.7.4 Non-significant positive correlation between cardiac ORAC and blood 
glucose concentrations. Spearman’s correlation coefficient r = 0.28, p=0.12. 
 
 
Figure 3.6.7.5 ORAC in the liver: A (combined data), B (WT STZ responders), C (WT STZ 
non-responders). Data presented as mean ± SEM, n=8. WT STZ responders n=3 (B), WT 
STZ non-responders n=5, (C). **p<0.01 vs. WT control, $p<0.05 vs. WT STZ. 






























 Spearman r = 0.28 p=0.12





Figure 3.6.7.6 No correlation between hepatic ORAC and blood glucose concentrations. 
Spearman’s correlation coefficient r = 0.04, p=0.82. 
 
3.6.8 The glutathione system 
The glutathione replenishment system is an important contributor to anti-oxidant capacity. We 
evaluated glutathione in its reduced (GSH) and oxidized (GSSG) forms, and also the ratio 
(GSH:GSSG). GSH was not significantly altered in the blood, heart, or liver. The GSH:GSSG 
ratio of hepatic tissue was decreased in the TKTL1-KO STZ group (p<0.05 vs. TKTL1-KO 
control, Figure 3.6.8.13). The liver GSH:GSSG ratio was also negatively correlated with blood 
glucose levels (r=-0.36, p=0.03, Figure 3.6.8.1). 
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Figure 3.6.8.1 GSH in circulation: A (combined data), B (WT STZ responders), C (WT STZ 
non-responders). Data presented as mean ± SEM, n=10. WT STZ responders n=4 (B), WT 
STZ non-responders n=6, (C). 
 
 
Figure 3.6.8.2 No correlation between GSH in the blood and blood glucose 
concentrations. Spearman’s correlation coefficient r = 0.14, p=0.37. 























 Spearman r = 0.14 p=0.37





Figure 3.6.8.3 GSSG in circulation: A (combined data), B (WT STZ responders), C (WT 
STZ non-responders). Data presented as mean ± SEM, n=10. WT STZ responders n=4 (B), 
WT STZ non-responders n=6, (C). 
 
 
Figure 3.6.8.4 No correlation between GSSG in the blood and blood glucose 
concentrations. Spearman’s correlation coefficient r = -0.16, p=0.32. 
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Figure 3.6.8.5 GSH:GSSG in circulation: A (combined data), B (WT STZ responders), C 
(WT STZ non-responders). Data presented as mean ± SEM, n=10. WT STZ responders n=4 
(B), WT STZ non-responders n=6, (C). 
 
 
Figure 3.6.8.6 No correlation between the blood GSH:GSSG and blood glucose 
concentrations. Spearman’s correlation coefficient r = 0.16, p=0.31. 






















 Spearman r = 0.16 p=0.31





Figure 3.6.8.7 GSH in the heart: A (combined data), B (WT STZ responders), C (WT STZ 
non-responders). Data presented as mean ± SEM, n=8. WT STZ responders n=3 (B), WT 
STZ non-responders n=5, (C). 
 
 
Figure 3.6.8.8 Non-significant positive correlation between GSH in heart tissue and 
blood glucose concentrations. Spearman’s correlation coefficient r = 0.33, p=0.06. 































 Spearman r = 0.33 p=0.06





Figure 3.6.8.9 GSH in the liver: A (combined data), B (WT STZ responders), C (WT STZ 
non-responders). Data presented as mean ± SEM, n=8. WT STZ responders n=3 (B), WT 
STZ non-responders n=5, (C). 
 
 
Figure 3.6.8.10 No correlation between GSH in liver tissue and blood glucose 
concentrations. Spearman’s correlation coefficient r = -0.22, p=0.21. 






































 Spearman r = -0.22 p=0.21





Figure 3.6.8.11 GSSG in the liver: A (combined data), B (WT STZ responders), C (WT STZ 
non-responders). Data presented as mean ± SEM, n=8. WT STZ responders n=3 (B), WT 
STZ non-responders n=5, (C). 
 
 
Figure 3.6.8.12 Non-significant positive correlation between GSSG in liver tissue and 
blood glucose concentrations. Spearman’s correlation coefficient r = 0.29, p=0.09. 
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Figure 3.6.8.13 GSH:GSSG in the liver: A (combined data), B (WT STZ responders), C 
(WT STZ non-responders). Data presented as mean ± SEM, n=8. WT STZ responders n=3 
(B), WT STZ non-responders n=5, (C). #p<0.05 vs TKTL1-KO control. 
 
 
Figure 3.6.8.14 Significant negative correlation between GSH:GSSG in liver tissue and 
blood glucose concentrations. Spearman’s correlation coefficient r = -0.36, p=0.03. 
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3.7 H&E staining of heart and liver sections  
Subsequent to the evaluation of oxidative stress, we aimed to acquire ultrastructural data of 
heart and liver samples by H&E staining. Heart sections did not show discernable differences 
between groups (Figure 3.7.1). In liver tissue (Figure 3.7.2), STZ treated groups showed clear 
deposits most likely to be glycogen or lipid deposits that seemed to be more pronounced in 
the TKTL1-KO STZ group (Figure 3.7.2E). 
 
Figure 3.7.1 H&E stain of heart tissue 20X magnification (n=2). None of the groups 
displayed notable ultrastructural differences. Scale bar denotes 100 µm. A: WT control, B: WT 
STZ, C: TKTL1-KO Control, D: TKTL1-KO STZ. 





Figure 3.7.2 H&E stain of liver tissue 20X magnification (n=4). Both STZ groups (B&D) 
displayed what looked like lipid or glycogen deposits (indicated by yellow arrows). This 
supports the data from liver weight analysis that indicated increased liver weights in groups 
treated with STZ especially the TKTL1-KO STZ (D) group. Scale bar denotes 100 µm. A: WT 
control, B: WT STZ, C: TKTL1-KO Control, D: TKTL1-KO STZ. 
  




3.8 Sirius red staining of heart and liver sections 
We also subjected heart and liver sections to Sirius red staining to discern whether oxidative 
perturbations possibly manifested in fibrosis. Due to a low number of hearts available for 
histological processing (Figure 3.7.1), we were unable to quantify the images. However, the 
two TKTL1-KO groups displayed relatively larger regions of fibrosis (indicated by yellow 
arrows). Fibrosis in liver samples was quantified as described by Hadi and colleagues (2011) 
using whole section images (Figure 3.7.2). Tissue processing imperfections, such as folding 
of sections, were excluded to limit bias. Both STZ groups displayed a reduced amount of 
fibrotic regions compared to the control groups (fibrotic regions indicated by yellow arrows). 
Initially, this was thought to be due to increased blood vessels present in the control groups. 
However, at 20X magnification (Figure 3.7.3) it was clear that fibrous regions were present in 
areas not localized to blood vessel regions. 
 
Figure 3.8.1 Sirius red stain of heart tissue 20X magnification (n=2). Scale bar denotes 
100 µm, yellow arrows indicate fibrotic regions. A: WT control, B: WT STZ, C: TKTL1-KO 
Control, D: TKTL1-KO STZ. 





Figure 3.8.2 Sirius red stain of liver tissue. (A-E) Shows Sirius red stain of liver tissue at 4X 
magnification (n=4). The fibrosis present in both control group is higher than that of the STZ 
groups with the TKTL1-KO control group displaying a significantly higher presence of fibrosis 
compared to both the WT and KO control, p<0.05. It is worth noting that the control groups 
display more blood vessels surrounded by connective tissue that is not present to such an 
extent in the STZ group. Data presented as mean ± SEM, #p<0.05 vs. TKTL1-KO control. 
Scale bar denotes 100 µm, yellow arrows indicate fibrotic regions. A: WT control, B: WT STZ, 
C: TKTL1-KO Control, D: TKTL1-KO STZ. 





Figure 3.8.3 Sirius red stain of liver tissue 20X magnification (n=4). Upon closer inspection 
of the Sirius red stains of the liver tissue, the control groups display signs of fibrosis that are 
not limited to only the blood vessel region (indicated by yellow arrows). This is not observed 
in either of the STZ treated groups. A: WT control, B: WT STZ, C: TKTL1-KO Control, D: 
TKTL1-KO STZ. 
 
3.9 Semi-quantitative protein analysis with Western Blotting 
We further aimed to assess apoptosis in heart and liver tissues by evaluating caspase-3 
cleavage. Both TKTL1-KO groups exhibited significantly higher levels of cleaved caspase 3 
(cCas-3) (17 kDa) in the heart. Although total caspase 3 could not be quantified, we can infer 
that more apoptosis was present in the TKTL1-KO groups of the heart. No significant 
differences in cCas-3 were observed in the liver of any of the groups. STZ treated groups 
displayed a slight and insignificant increase in cCas-3 3 compared to their respective controls. 
  





Figure 3.9.1 Western blot analysis of cleaved Caspase 3 (cCas-3) in the heart (A&C) and 
liver (B&D). Data presented as mean ± SEM. 
  




Chapter 4: Discussion 
Diabetes is a growing, global concern that has reached a prevalence far beyond the projected 
statistics. Hyperglycemia is a common denominator of T1DM and T2DM and results in 
excessive flux through pathways that can elicit damaging outcomes, e.g. oxidative damage 
and inflammation. This can result in functional consequences at organ level and threaten 
overall well-being and health. The PPP offers an alternate ‟safer” route for excess metabolic 
fuels while also replenishing antioxidant defenses, thus potentially offering value as a novel 
therapeutic target. As a result, the current study focused on this pathway (and particularly 
TKTL1) as there are currently no studies – as far as we are aware – focusing on TKTL1 as a 
therapeutic target for cardio-metabolic diseases. In light of this, the current study evaluated 
whether TKTL1 can alleviate hyperglycemia-mediated oxidative stress in hepatic and cardiac 
tissues isolated from STZ-treated mice. 
The main findings of this study are: i) TKTL1 knock-out sensitized mice to the development of 
STZ-induced hyperglycemia; ii) TKTL1-KO mice treated with STZ displayed enlarged livers 
and kidneys while gastrocnemii weight was reduced; iii) the PPP appear to possess distinct 
functional roles in the heart and the liver under hyperglycemic conditions, iv) TKTL1 
contributed significantly towards total TKT activity in cardiac tissue; and v) while measures of 
oxidative damage remained relatively unchanged, antioxidant defenses (catalase activity, 
FRAP levels and the GSH:GSSG ratio) displayed some adaptations in the liver of STZ-treated 
KO animals. 
The protocol of multiple low dose of STZ injection was chosen as it causes inflammation of 
pancreatic β-cells and insulin deficiency, thereby leading to hyperglycemia and subsequent 
oxidative damage, both of which were of interest to this study (Furman, 2015). Female mice 
are known to be resistant towards STZ treatment as confirmed by this study (Friesen et al., 
2004; Furman, 2015). This may be a result of upregulated antioxidant defenses that protect 
against STZ insults and/or due to the protective effect of estrogen that prevents inflammation 




and also increases insulin sensitivity (Friesen et al., 2004; Manrique et al., 2012; Shen et al., 
2014). As female mice did not develop hyperglycemia, we excluded them from subsequent 
experiments and instead focused on males. 
The incidence of hyperglycemia in STZ-treated WT and TKTL1-KO groups were 40% and 
90%, respectively. Previous studies utilizing the multiple low-dose STZ injection protocol on 
C57BL/6 mice reported mixed results regarding the hyperglycemia onset. For example, 
Hӓssler and colleagues (2008) found that only 25% of C57BL/6 mice developed 
hyperglycemia (21 days after injections) whereas Fukudome and colleagues (2008) noted that 
~80% of the same strain developed hyperglycemia in a similar period. The protocol selected 
for this study projected that hyperglycemia would be detectible in ~50% of mice three weeks 
after injections (Furman, 2015). However, this did not materialize with more than 60% of mice 
unresponsive by the end of week 4. For this study, a second set of injections was not possible 
as the risk of mortality in the STZ-treated TKTL1-KO group (presenting with hyperglycemia) 
was too high. Thus we propose that our STZ model represents an experimental system of 
moderate hyperglycemia and we expected that associated changes (liver, heart) would 
therefore not be as pronounced as originally predicted. In support, the STZ treatment protocol 
was not harsh enough to induce significant damage to macromolecules, i.e. lipid peroxidation, 
while expression of a downstream marker for apoptosis (caspase 3) was also not significantly 
different compared to the various controls. However, it can also be interpreted that alterations 
observed in our model would represent relatively early changes triggered in response to the 
stimulus and therefore still provide value in terms of deciphering the role of TKTL1 within this 
context. 
The most striking finding of this study is the robust difference between the WT and TKTL1-
KO’s response to STZ treatment, with the latter developing hyperglycemia at a faster rate and 
to a greater extent. Thus it supports our premise that TKTL1 offers therapeutic value within 
the context of diabetes as its lack is linked to hyperglycemia. However, it also raises an 
unexpected rhetorical question, i.e. how exactly does TKTL1 regulate systemic glucose 




levels? We are unable to provide a firm answer at present to this intriguing question but here 
put forward several proposals, focusing mainly on changes in the liver.  
The oxidative stress data generally showed no changes in NOX activity and the lipids 
remained relatively protected from oxidative damage (CDs and TBARS). It may be useful to 
investigate other sources of ROS production (e.g. mitochondrial-derived) and assess 
additional markers of oxidative damage (e.g. protein carbonylation). Our laboratory previously 
found that different ROS sources (mitochondrial and NOX) may be triggered in response to 
experimental hyperglycemia and there may be a complex interplay between these processes 
(Joseph et al. 2014; Mapanga et al. 2012, 2014). The elevated ROS levels observed in these 
studies were accompanied by decreased antioxidant system activity and induction of lipid 
peroxidation and protein carbonylation. By contrast to the current study, glucose levels 
reported there were considerably higher in in vitro, ex vivo and in vivo experimental conditions. 
For example, Mapanga et al. (2012) showed that single high dose STZ injections in rats 
resulted in mean blood glucose levels exceeding 25 mmol/L compared to ~14.5 mmol/L in our 
study (in WT responders and KO mice). The severity of hyperglycemia may be an important 
consideration and, as mentioned above, higher blood glucose levels (and greater 
hyperglycemia incidence in the WT group), could have translated into more pronounced 
oxidative stress. Despite this the STZ treatment seemed to elicit mild changes in the liver 
antioxidant systems of the TKTL1-KO mice. Here we observed increased catalase activity, a 
decreased GSH:GSSG ratio and lower FRAP levels. These markers also correlated 
significantly with blood glucose levels. Together these data suggest that the hepatic 
antioxidant capacity may be de-sensitized, even under the relatively “mild” hyperglycemic 
conditions in our model. We argue that the fact that this only occurred in the KO group points 
toward a role for TKTL1 in the maintenance of antioxidant systems. The small alterations in 
hepatic antioxidant capacity could in turn induce dysregulation of glucose metabolic processes 
in the liver. 




Alternatively, TKTL1 may play a direct inhibitory role in the gluconeogenesis and/or glycogen 
breakdown pathways to thereby contribute to increased blood glucose levels observed. 
Although the findings of this study are generally in agreement with this proposal, further 
studies are required to ascertain which proposal is indeed the correct one. 
It is also possible that TKTL1 lack may influence the insulin secretion pathway in pancreatic 
β–cells, leading to a lower secretion of insulin and hence increased glucose levels. We did 
unfortunately not assess systemic insulin levels for this project, but such data would be 
invaluable to help unravel the TKTL1 mystery. Increased oxidative stress in such cells (due to 
TKTL1 lack) may lead to DNA damage, and AGE formation to uncouple glucose sensing from 
insulin secretion (reviewed in Cerf, 2013, reviewed in Cichoż-Lach and Michalak, 2014). STZ 
is a glucose and GlcNAc analog that exerts its cytotoxic effects mainly on pancreatic β-cells 
(Junod et al., 1967). The reason for this specificity is due to GLUT-2 availability on β-cell 
membranes which provides a shuttle for STZ into such cells (Schnedl et al., 1994; Wang and 
Gleichmann, 1998). Subsequently, the alkylnitroso moiety of STZ directly and indirectly (via 
generation of ROS and RNS) causes DNA damage which activates PARP to repair the strand 
breaks (Figure 4.1) (Szabó and Dawson, 1998). According to the suicide theory of PARP 
activation described by Szabó and Dawson, its activation leads to the depletion of NAD+ which 
causes a decrease in glycolysis, TCA cycling, and PPP flux due to insufficient NAD+ 
conversion to NADP+. Moreover, PARP has also been link to the recruitment of thymus (T)-
cells and monocytes and resultant inflammation and oxidative stress (reviewed in Ba and 
Garg, 2011). In support, the only previous study that employed the TKTL1-KO mice (in an 
experimental model of colitis) found that they were more prone to the development of 
inflammation compared to WT mice (Bentz et al., 2011). Here the colon of TKTL1-KO mice 
exposed to the colitis-inducing agent presented with a higher histological score (an indication 
of disease severity) than the WT group receiving the same treatment. Hence we propose that 
TKTL1 acts as a contributor to TKT activity to promote PPP flux that replenishes antioxidant 
capacity (Figure 4.1). Moreover, TKTL1 may delay and/or partially prevent the infiltration of 




immune cells and subsequent inflammation by augmenting the pancreatic -cell’s antioxidant 
defense system. These proposals also require further investigation.






Figure 4.1 TKTL1 offers protection against STZ. A) STZ mechanism of action in TKTL1-KO mice: 
STZ enters pancreatic β-cells via GLUT-2 where the alkylnitroso moiety alkylates DNA thereby causing 
damage. STZ can also induce the formation of reactive species such as NO and ONOO- which can 
cause further damage to DNA and other macromolecules. PARP is activated to restore DNA strand 
breaks and as a result NAD⁺ is depleted causing a decrease in glycolysis, TCA cycling and PPP flux 
eventually leading to an exhaustion of ATP stores. PARP can also lead to the recruitment and infiltration 
of immune cells which contribute to accumulating reactive species. The combination of ROS and RNS 
build-up and inflammatory environment together with ATP depletion can lead to β-cell toxicity and 
dysfunction as well as cell death most likely via necrosis. Thus, β-cell mass decreases and insulin 
production and secretion ceases leading to chronic hyperglycemia. B) STZ mechanism of action in 
WT mice: WT mice possess the TKTL1 gene which contributes to TKT activity and can therefore alter 
PPP flux. By increasing PPP flux, more NADPH is produced which can replenish glutathione antioxidant 
capacity thereby neutralizing some of the harmful ROS and RNS that accumulate within the cell and 
surrounding environment and thus, decrease the inflammatory response. Red dotted line indicates 
decrease with harmful consequences, green arrows indicates increase with positive outcomes, green 
dotted line indicates decrease with positive outcomes.  




The PPP data suggest distinct functional roles in the heart and liver. For hepatic tissues we 
found that G6PD activity (rate-limiting enzyme of PPP oxidative branch) negatively correlated 
with blood glucose levels whereas the heart did not display any correlation. This suggests that 
the heart may be less susceptible to hyperglycemic oxidative damage compared to the liver, 
as G6PD activity in cardiac tissue was intact. If indeed the case, it may offer an explanation 
for our oxidative stress data where the hepatic tissues were more responsive to STZ-induced 
hyperglycemia. NADPH levels would be expected to follow the same trend as G6PD activity, 
but as only NAPDt levels (NADPH + NADP+) could be measured (technical difficulties - refer 
Materials and methods section) this remains to be determined. An additional consideration is 
the presence of GLUT-2 in hepatocytes which provide a point of entry for STZ and could 
provide another explanation for the oxidative data obtained in this study (Mueckler, 1994).  
Evaluation of the non-oxidative branch of the PPP produced a similar pattern. Perplexingly, 
the assay that was performed on hepatic tissue showed negative values which at first glance 
appear nonsensical. However, the assay quantifies relative NADH levels as a measure of 
transketolase activity as NADH is consumed in a downstream reaction. Therefore, if other 
reactions that produce NADH occur simultaneously, it may result in the negative values here 
obtained. It is crucial here to bear in mind that overall metabolic functioning and negative 
values obtained could be due to organ-specific metabolism. The liver is a dominant player in 
metabolism and is responsible for a great fraction of glucose disposal. Under postprandial 
conditions, excess glucose enters hepatocytes either to be stored as glycogen or to enter lipid 
biosynthesis (reviewed in Rui, 2014). Glucose that is stored as fatty acids proceed via 
glycolysis and the TCA cycle, both of which produces NADH. Thus if NADH is produced more 
rapidly than it is consumed through the reaction downstream of the TKT catalyzed reaction, 
then negative values will be obtained. 
From the TKT activity assay performed on cardiac tissue, it is evident that TKTL1 may 
contribute to a significant portion of total TKT activity – at least in the heart. Interestingly, this 
seems to be the case irrespective of hyperglycemia, as both the STZ-responders and non-




responders showed a relatively similar decrease in TKT activity in WT mice. For both TKTL1-
KO groups a ~50% activity was observed indicating that STZ resulted in no further effects on 
TKT activity. In addition, there was no difference in TKT activity in the responder and non-
responder STZ-treated WT mouse groups. Together this suggests that the inhibitory effect of 
STZ on TKT activity may not be due to hyperglycemia per se. This is in contrast to other data 
where decreased transketolase activity occurred as a direct result of hyperglycemia (Mapanga 
et al., 2014) and also by others that utilized the same STZ-treatment protocol (Katare et al., 
2013). A possible explanation for these data may be that in our study the mechanism of STZ 
action impacted negatively on TKT activity as it is able to downregulate the PPP (Figure 4.1). 
Importantly, these data indicate that TKTL1 may contribute significantly to total transketolase 
activity in the heart. 
The TKT data are complex and other interpretations should also be considered.  Our findings 
(lower WT TKT activity with hyperglycemia) are in agreement with previous studies (Saito et 
al., 1987) and thus strengthen overall data here generated.  The significant decrease in TKT 
activity in STZ KO mice versus STZ WT mice should also be considered. One possibility is 
that this means that TKTL1 contributes to overall TKT activity (to a significant extent) and that 
it may actually be upregulated under pre-diabetic and diabetic conditions to counteract the 
overall decrease in TKT activity observed.  This is in agreement with previous data generated 
in the Essop laboratory that found increased TKTL1 gene expression in pre-diabetic and 
diabetic individuals.  Moreover, STZ treatment did not further decrease TKT activity in the KO 
mice as would be expected.  It is not entirely clear why this is the case and this requires further 
investigations. We speculate that there may be some compensatory mechanisms at play that 
prevented lower TKT activity as expected. It is possible that there may be a threshold value to 
ensure a minimal degree of intracellular TKT activity, and that at this point compensatory 
mechanisms are triggered to sustain its function.  Such mechanisms remain unclear at this 
time, but it is possible that other isoforms such as TKTL2 may be upregulated in this instance. 
However, this notion requires further investigations.    




Limitations and future studies 
The TKT activity assay was based on a published in-house assay and was technically 
challenging and very expensive to set up in our laboratory.  Thus the liver TKT activity data 
did not reveal optimal results as expected and requires further optimization. An additional 
limitation was the nature of the TKTL1 antibody used as there is currently a lack of 
commercially available TKTL1 antibodies that can generate reproducible data. 
For future studies, we recommend that the STZ injection protocol be amended in order to 
achieve a greater degree of hyperglycemia. We now propose to use a single high dose 
protocol that should elicit significant effects.  In addition, studies should be planned to generate 
a T2DM phenotype in WT and KO mice and to assess the role of TKTL1 within this context.  
Here feeding mice a high-fat and high carbohydrate diet should ensure increased weight gain 
and the onset of insulin resistance and diabetes.  It is also our aim to design new antibodies 
(in-house) for TKTL1 that should allow for improved detection (and reproducibility) of this 
crucial protein.  Finally, it is crucial to investigate in more detail the various mechanisms that 
contribute to overall TKT activity as this not well understood at present.      
In summary, the current study shows that TKTL1 may play distinct roles in the liver and heart. 
Our data reveal that it plays an anti-oxidant role in the liver to protect against hyperglycemia 
and to maintain overall glucose homeostasis. Here we speculate that TKTL1 lack results in 
residual oxidative stress that may result in downstream effects impacting on hepatic insulin 
signaling, gluconeogenesis and glycogen breakdown (Figure 4.2). Thus our study 
demonstrates novel insights into TKTL1 function and shows that it remains a feasible 
therapeutic target for the treatment of diabetes. However, as with any good research study it 
has unearthed several new questions and leads that require extensive investigation to help 
unravel the mysteries of TKTL1. 
  





Figure 4.2 Proposed regulatory role for TKTL1 in glucose metabolism. Pancreatic β-cells: STZ mainly targets pancreatic β-cells where it 
elicits various damaging mechanisms that can lead to impaired insulin signaling and disengagement between glucose sensing and insulin 
secretion. This eventually results in a relative insulin deficiency and hyperglycemia. We propose that the anti-ROS and possible anti-inflammatory 
effect of TKTL1 enables it to alleviate some of these processes thereby at least partially preventing hyperglycemia. Hepatocytes: STZ-induced 
NF-κB activation and subsequent inflammation can lead to insulin resistance and steatosis which impairs insulin signaling. In hepatocytes this 
can lead to decreased insulin secretion as well as an increase in glycogen breakdown and gluconeogenesis all of which contribute to 
hyperglycemia. Here we propose that TKTL1 is able to minimize the damage of this dysregulation either via its anti-ROS function or a yet to be 
determined mechanism unique to this enzyme. Green dotted line indicates where TKTL1 may have an inhibitory role. 
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Appendix B: Table with correlations between blood glucose levels and experimental 
values. 
Variable 1 Variable 2 Spearman r p-value Subgroup 
Blood glucose 
(mmol/L) 
Heart G6PD activity (mU/mg 
protein) 
0,03 0,87 N/A 
Blood glucose 
(mmol/L) 
Liver G6PD activity (mU/mg 
protein) 
-0,37 0,03 N/A 
Blood glucose 
(mmol/L) 
Heart NADPt (nmol/mg 
protein) 
0,11 0,56 N/A 
Blood glucose 
(mmol/L) 
Liver NADPt (nmol/mg 
protein) 
-0,13 0,44 N/A 
Blood glucose 
(mmol/L) 
Heart TKT activity (uU/g 
protein) 
-0,07 0,71 N/A 
Blood glucose 
(mmol/L) 
Liver TKT activity (uU/g 
protein) 
-0,30 0,08 N/A 
Blood glucose 
(mmol/L) 
Heart SOD activity (U/mg 
protein) 
-0,09 0,63 N/A 
Blood glucose 
(mmol/L) 
Liver SOD activity (U/mg 
protein) 
-0,08 0,65 N/A 
Blood glucose 
(mmol/L) 
Heart Catalase activity 
(umol/min/mg protein) 
-0,02 0,89 N/A 
Blood glucose 
(mmol/L) 
Liver Catalase activity 
(umol/min/mg protein) 
0,39 0,02 N/A 
Blood glucose 
(mmol/L) 
Heart NADPH oxidase 
activity (RLU/mg protein) 
-0,11 0,55 N/A 
Blood glucose 
(mmol/L) 
Liver NADPH oxidase 
activity (RLU/mg protein) 
-0,11 0,54 N/A 
Blood glucose 
(mmol/L) 
Blood CDs (umol/L) -0,17 0,31 N/A 
Blood glucose 
(mmol/L) 
Heart CDs (umol/g tissue) 0,05 0,78 N/A 
Blood glucose 
(mmol/L) 
Liver CDs (umol/g tissue) -0,09 0,59 N/A 
Blood glucose 
(mmol/L) 
Blood TBARS (umol/L) -0,17 0,33 N/A 




Variable 1 Variable 2 Spearman r p-value Subgroup 
Blood glucose 
(mmol/L) 
Heart TBARS (umol/mg 
tissue) 
0,08 0,67 N/A 
Blood glucose 
(mmol/L) 
Liver TBARS (umol/mg 
tissue) 
0,05 0,76 N/A 
Blood glucose 
(mmol/L) 
Blood FRAP (umol/L) -0,26 0,12 N/A 
Blood glucose 
(mmol/L) 
Heart FRAP (umol/g tissue) 0,02 0,92 N/A 
Blood glucose 
(mmol/L) 
Liver FRAP (umol/g tissue) -0,45 <0.01 N/A 
Blood glucose 
(mmol/L) 
Blood ORAC (TE/L) 0,04 0,82 N/A 
Blood glucose 
(mmol/L) 
Heart ORAC (TE/g tissue) 0,28 0,12 N/A 
Blood glucose 
(mmol/L) 
Liver ORAC (TE/g tissue) 0,04 0,82 N/A 
Blood glucose 
(mmol/L) 
Blood GSH (umol/L) 0,14 0,37 N/A 
Blood glucose 
(mmol/L) 
Heart GSH (umol/g tissue) 0,33 0,06 N/A 
Blood glucose 
(mmol/L) 
Liver GSH (umol/g tissue) -0,22 0,21 N/A 
Blood glucose 
(mmol/L) 
Blood GSSG (umol/L) -0,16 0,32 N/A 
Blood glucose 
(mmol/L) 
Liver GSSG (umol/g tissue) 0,29 0,09 N/A 
Blood glucose 
(mmol/L) 
Blood GSH: GSSG 0,16 0,31 N/A 
Blood glucose 
(mmol/L) 





-0,16 0,32 N/A 
Blood glucose 
(mmol/L) 
Blood GSH: GSSG(BoxCox) 0,16 0,31 N/A 
Blood glucose 
(mmol/L) 
Heart G6PD activity (mU/mg 
protein) 
-0,07 0,80 KO 




Variable 1 Variable 2 Spearman r p-value Subgroup 
Blood glucose 
(mmol/L) 
Liver G6PD activity (mU/mg 
protein) 
-0,40 0,10 KO 
Blood glucose 
(mmol/L) 
Heart NADPt (nmol/mg 
protein) 
-0,13 0,63 KO 
Blood glucose 
(mmol/L) 
Liver NADPt (nmol/mg 
protein) 
-0,35 0,15 KO 
Blood glucose 
(mmol/L) 
Heart TKT activity (uU/g 
protein) 
-0,06 0,81 KO 
Blood glucose 
(mmol/L) 
Liver TKT activity (uU/g 
protein) 
-0,42 0,08 KO 
Blood glucose 
(mmol/L) 
Heart SOD activity (U/mg 
protein) 
-0,37 0,16 KO 
Blood glucose 
(mmol/L) 
Liver SOD activity (U/mg 
protein) 
-0,25 0,32 KO 
Blood glucose 
(mmol/L) 
Heart Catalase activity 
(umol/min/mg protein) 
0,21 0,43 KO 
Blood glucose 
(mmol/L) 
Liver Catalase activity 
(umol/min/mg protein) 
0,53 0,02 KO 
Blood glucose 
(mmol/L) 
Heart NADPH oxidase 
activity (RLU/mg protein) 
-0,14 0,60 KO 
Blood glucose 
(mmol/L) 
Liver NADPH oxidase 
activity (RLU/mg protein) 
-0,04 0,86 KO 
Blood glucose 
(mmol/L) 
Blood CDs (umol/L) -0,04 0,86 KO 
Blood glucose 
(mmol/L) 
Heart CDs (umol/g tissue) 0,13 0,62 KO 
Blood glucose 
(mmol/L) 
Liver CDs (umol/g tissue) 0,29 0,25 KO 
Blood glucose 
(mmol/L) 
Blood TBARS (umol/L) -0,14 0,58 KO 
Blood glucose 
(mmol/L) 
Heart TBARS (umol/mg 
tissue) 
0,02 0,93 KO 
Blood glucose 
(mmol/L) 
Liver TBARS (umol/mg 
tissue) 
0,04 0,86 KO 
Blood glucose 
(mmol/L) 
Blood FRAP (umol/L) -0,32 0,17 KO 




Variable 1 Variable 2 Spearman r p-value Subgroup 
Blood glucose 
(mmol/L) 
Heart FRAP (umol/g tissue) 0,22 0,42 KO 
Blood glucose 
(mmol/L) 
Liver FRAP (umol/g tissue) -0,54 0,02 KO 
Blood glucose 
(mmol/L) 
Blood ORAC (TE/L) 0,20 0,40 KO 
Blood glucose 
(mmol/L) 
Heart ORAC (TE/g tissue) 0,16 0,54 KO 
Blood glucose 
(mmol/L) 
Liver ORAC (TE/g tissue) -0,25 0,31 KO 
Blood glucose 
(mmol/L) 
Blood GSH (umol/L) 0,21 0,38 KO 
Blood glucose 
(mmol/L) 
Heart GSH (umol/g tissue) 0,47 0,07 KO 
Blood glucose 
(mmol/L) 
Liver GSH (umol/g tissue) -0,25 0,32 KO 
Blood glucose 
(mmol/L) 
Blood GSSG (umol/L) -0,25 0,29 KO 
Blood glucose 
(mmol/L) 
Liver GSSG (umol/g tissue) 0,32 0,20 KO 
Blood glucose 
(mmol/L) 
Blood GSH: GSSG 0,30 0,20 KO 
Blood glucose 
(mmol/L) 





-0,25 0,29 KO 
Blood glucose 
(mmol/L) 
Blood GSH: GSSG(BoxCox) 0,30 0,20 KO 
Blood glucose 
(mmol/L) 
Heart G6PD activity (mU/mg 
protein) 
0,06 0,83 WT 
Blood glucose 
(mmol/L) 
Liver G6PD activity (mU/mg 
protein) 
-0,35 0,17 WT 
Blood glucose 
(mmol/L) 
Heart NADPt (nmol/mg 
protein) 
0,32 0,22 WT 
Blood glucose 
(mmol/L) 
Liver NADPt (nmol/mg 
protein) 
0,20 0,44 WT 




Variable 1 Variable 2 Spearman r p-value Subgroup 
Blood glucose 
(mmol/L) 
Heart TKT activity (uU/g 
protein) 
-0,10 0,71 WT 
Blood glucose 
(mmol/L) 
Liver TKT activity (uU/g 
protein) 
-0,27 0,30 WT 
Blood glucose 
(mmol/L) 
Heart SOD activity (U/mg 
protein) 
-0,04 0,90 WT 
Blood glucose 
(mmol/L) 
Liver SOD activity (U/mg 
protein) 
0,12 0,64 WT 
Blood glucose 
(mmol/L) 
Heart Catalase activity 
(umol/min/mg protein) 
-0,20 0,45 WT 
Blood glucose 
(mmol/L) 
Liver Catalase activity 
(umol/min/mg protein) 
0,25 0,34 WT 
Blood glucose 
(mmol/L) 
Heart NADPH oxidase 
activity (RLU/mg protein) 
-0,17 0,53 WT 
Blood glucose 
(mmol/L) 
Liver NADPH oxidase 
activity (RLU/mg protein) 
0,05 0,84 WT 
Blood glucose 
(mmol/L) 
Blood CDs (umol/L) -0,28 0,25 WT 
Blood glucose 
(mmol/L) 
Heart CDs (umol/g tissue) -0,03 0,91 WT 
Blood glucose 
(mmol/L) 
Liver CDs (umol/g tissue) -0,47 0,05 WT 
Blood glucose 
(mmol/L) 
Blood TBARS (umol/L) -0,27 0,30 WT 
Blood glucose 
(mmol/L) 
Heart TBARS (umol/mg 
tissue) 
-0,00 1,00 WT 
Blood glucose 
(mmol/L) 
Liver TBARS (umol/mg 
tissue) 
0,05 0,85 WT 
Blood glucose 
(mmol/L) 
Blood FRAP (umol/L) -0,28 0,24 WT 
Blood glucose 
(mmol/L) 
Heart FRAP (umol/g tissue) -0,12 0,65 WT 
Blood glucose 
(mmol/L) 
Liver FRAP (umol/g tissue) -0,27 0,30 WT 
Blood glucose 
(mmol/L) 
Blood ORAC (TE/L) -0,21 0,37 WT 




Variable 1 Variable 2 Spearman r p-value Subgroup 
Blood glucose 
(mmol/L) 
Heart ORAC (TE/g tissue) 0,36 0,17 WT 
Blood glucose 
(mmol/L) 
Liver ORAC (TE/g tissue) 0,07 0,78 WT 
Blood glucose 
(mmol/L) 
Blood GSH (umol/L) -0,03 0,90 WT 
Blood glucose 
(mmol/L) 
Heart GSH (umol/g tissue) 0,17 0,52 WT 
Blood glucose 
(mmol/L) 
Liver GSH (umol/g tissue) -0,12 0,65 WT 
Blood glucose 
(mmol/L) 
Blood GSSG (umol/L) -0,13 0,59 WT 
Blood glucose 
(mmol/L) 
Liver GSSG (umol/g tissue) 0,12 0,65 WT 
Blood glucose 
(mmol/L) 
Blood GSH: GSSG 0,08 0,73 WT 
Blood glucose 
(mmol/L) 





-0,13 0,59 WT 
Blood glucose 
(mmol/L) 
Blood GSH: GSSG(BoxCox) 0,08 0,73 WT 
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